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The phosphatidylinositide 3 kinase (PI3K)/Akt signaling network plays a pivotal role
in multiple cellular functions. PI3K links the extracellular growth factor receptors to the
serine-threonine kinase Akt which, through phosphorylation of numerous intracellular
proteins, mediates increased cell growth, survival, motility and proliferation. The
significance of the PI3K/Akt signaling network to human malignancy is demonstrated by
cancer-associated genetic aberrations at multiple levels in the PI3K/Akt pathway in many
tumor lineages. These aberrations include mutation or amplification of Akt, catalytic and
regulatory subunits of PI3K, and growth factor receptors upstream of PI3K. Inactivating
mutations and decreased expression of the PTEN, a major antagonist of PI3K signaling, also
lead to constitutive hyperactivity of Akt.
Multiple small molecule inhibitors targeting components of the PI3K/Akt signaling
pathway including Akt catalytic domain inhibitors, significantly slow tumor growth in
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preclinical models. Strikingly, these Akt kinase inhibitors induce a paradoxical increase in
phosphorylation of Akt activation sites. As Akt catalytic domain inhibitors are entering
clinical trials, elucidation of the mechanism(s) underlying Akt inhibitor-induced Akt
phosphorylation is needed to understand and anticipate drug effects.
In this study, we demonstrate an unexpected requirement of Glycogen Synthase
Kinase 3 (GSK3), a serine-threonine kinase that participates in multiple cell signaling
pathways downstream of Akt, for Akt inhibitor-induced Akt phosphorylation. siRNAmediated knockdown of GSK3 in MDAMB231 breast cancer cells and in mouse embryonic
fibroblasts (MEFs) abrogated induction of Akt phosphorylation by the Akt catalytic domain
inhibitor A674563. Our discovery that GSK3 can function upstream of Akt led us to explore
the role of GSK3 in mediating signaling from growth factors to Akt. Knockdown of GSK3
expression in MDAMB231 cells and in MEFs blocked stimulation of Akt phosphorylation
by epidermal growth factor (EGF) and insulin-like growth factor (IGF1).
The results, taken together, demonstrate a novel signaling role for GSK3 upstream of
Akt.
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CHAPTER 1: INTRODUCTION

1.1

PI3K/Akt Pathway

Phosphoinositide 3-kinases (PI3Ks)

The phosphoinositide 3-kinase (PI3K) family of lipid kinases functions near the
inner surface of the cell membrane to catalyze the phosphorylation of phosphatidylinositols
(PtdIns) on the D3 position of the inositol ring. The PI3K enzymes are divided into three
classes based on homology of the catalytic subunits and substrate specificity.

Class I PI3Ks can catalyze phosphorylation of the D3 site of PI(4)P or PI(4,5)P2
PtdIns in vitro, but the preferred in vivo substrate is PI(4,5)P2 (1). The phosphorylation of
PI(4,5)P2 (PIP2) by Class I PI3Ks generates the important second messenger PI(3,4,5)P3
(PIP3) which activates a multitude of downstream signaling processes leading to important
cellular process and outcomes. Class I PI3Ks are further divided into Class IA and Class IB
based on different enzyme regulatory unit structure and activation downstream of tyrosine
kinases (Class IA) versus G-protein coupled receptors (Class IB) (2).

Class II PI3Ks preferentially phosphorylate PtdIns and PtdIns-4-P (3). Class III
PI3Ks regulate intracellular trafficking through phosphorylation of PI to generate PI(3)P (1).
Detailed discussion of the important cellular processes mediated by Class II and Class III
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PI3Ks is outside the scope of this dissertation. The interested reader is referred to the
following sources for further detail (4, 5).

An extensive body of data implicates dysregulated signaling of Class IA PI3Ks in
human cancers. This work is focused only on the cellular signaling network of Class IA
PI3Ks. Throughout this work, use of the term PI3K will refer to the Class IA PI3K enzymes
that are discussed in detail below.

Class IA PI3K Structure

Class IA PI3Ks exist as a heterodimer containing a catalytic subunit and a regulatory
subunit. Multiple isoforms exist for both the catalytic and regulatory subunits. Three 110kD
proteins, p110α, p110β, and p110δ, encoded by distinct genes comprise the catalytic subunit
isoforms. p110α and p110β are ubiquitously expressed, while p110δ is expressed primarily
in leukocytes (6). The p85α and p85β genes encode two 85kD regulatory subunit isoforms.
Two truncated regulatory subunit isoforms, p55α and p50α, are produced as alternative
splice variants of p85α. A third gene, p55γ, encodes p55PIK (p55γ) and p50PIK (p50γ),
alternative translation initiation products (7). The regulatory subunit is commonly referred to
as p85 as the two 85 kDa isoforms were the first isoforms discovered.

The three p110 catalytic isoforms possess an N-terminal regulatory subunit-binding
domain and a C-terminal catalytic domain. The inner domains of the p110 isoforms are the
Ras-binding domain (RBD) that interacts with Ras in its active GTP-bound state, the
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phospholipid-binding C2 domain, and the helical PIK domain that is conserved among the
phosphatidyl inositol kinase (PIK) superfamily. The domain structure of the p110 catalytic
subunit is illustrated in Figure 1.1A.

Regulatory subunit isoforms all contain a proline-rich region, two Src homology 2
(SH2) domains and an inter-SH2 region that binds to p110. The larger (85kD) isoforms also
contain an N-terminal Src homogy 3 (SH3) domain, a breakpoint cluster region homology
(BH) domain, and an additional proline-rich region. Domain structure of p85 is depicted in
Figure 1.1B. p85 has multiple critical functions. It binds and stabilizes p110. Further it
inhibits p110, creating a pool of p110 that can be rapidly activated through relief of the
inhibitory effect of p85 by binding to phosphotyrosine residues at the cell membrane.
Recently, p85 has also been demonstrated to bind and regulate PTEN, the key negative
regulator in the PI3K pathway (8). Thus p85 provides an important point of integration of
information transfer in the PI3K pathway.

Phosphoinositide 3-kinase Activation by Receptor Tyrosine Kinases

Class IA PI3Ks are activated primarily as a consequence of extracellular binding of
growth factors to cell-surface receptors with intracellular tyrosine kinase domains. Binding
of the growth factor alters the conformation of the receptor tyrosine kinase (RTK),
activating transphosphorylation of intracellular tyrosine residues. The SH2 domains of the
regulatory subunit of PI3K bind specific phosphotyrosine residues of the receptor tyrosine
kinase. The binding of the PI3K regulatory subunit to the membrane-bound receptor brings

3

Figure 1.1 Domain structure of Class IA PI3K subunits. A. Domain structure of p110
catalytic subunit isoforms of Class IA PI3K contains a regulatory subunit-binding domain,
a Ras-binding domain, a phospholipid-binding C2 domain, phosphatidyl inositol kinase
(PIK) domain, and a catalytic domain. B. 85 kD regulatory subunits contain an N-terminal
Src homology 3 (SH3) domain, proline-rich (PR) region, breakpoint cluster region
homology (BH) domain, a second PR region, and two Src Homology 2 (SH2) domains
separated by a p110-binding domain. The 50-55 kD regulatory subunits contain one Nterminal PR, and the two SH2 domains separated by an inter-SH2 p110-binding domain.
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the PI3K catalytic subunit into proximity to its phosphoinositide substrate and also alters the
conformation of the PI3K dimer releasing the inhibitory effect of p85 on the activity of the
catalytic subunit. Phosphotyrosine residues on RTKs can also recruit PI3K to the cell
membrane indirectly through adaptor molecules that bind the PI3K regulatory subunit. The
catalytic subunit of PI3K can also be directly activated by Ras. Once activated, PI3K
catalyzes the phosphorylation of PI(4,5)P2 to generate PI(3,4,5)P3 (PIP3). PIP3 recruits
multiple proteins through specific phosphatidylinositol interaction domains such as the PH
(pleckstrin homology) domains to form an activation nidus at the cell membrane.

Akt Structure and Activation of Akt Downstream of PI3K

Akt (aka PKB of the AGC protein kinase family) comprises three isoforms – Akt1,
Akt2, and Akt3 - encoded by separate genes. The Akt structure consists of an N-terminal
PH-domain, a hinge region, an activation loop, and a C-terminal tail region that includes a
hydrophobic motif. Three Akt phosphorylation sites – the Thr308, Ser473, and Thr450
residues (Akt1 numbering) – regulate activation of Akt kinase activity. Figure 1.2 illustrates
the Akt structural domains and phosphorylation sites.

Both Akt and the Akt-activating kinase PDK1 are recruited to the cell membrane by
binding of their PH domains to PIP3. In lower organisms, the effects of PI3K can be
replaced by an activated Akt, suggesting that Akt is the major functional effector of PIP3.
However, in higher organisms, the multiple molecules recruited or activated by PIP3 suggest
a more complex relationship. Binding of the PH domain of Akt to PIP3 removes an
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Figure 1.2 Domain structure and phosphorylation sites of Akt.
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inhibitory effect of the PH domain on the activation loop, which allows PDK1 to
phosphorylate Akt on its Thr308 residue within the activation loop.

Phosphorylation of the Ser473 residue within the hydrophobic motif of Akt is
required for full activation of the kinase. Although the identity of the kinase responsible for
phosphorylating Akt on this site remains controversial, mTORC2 has recently been
established as a Ser473 kinase of Akt (9). However, PDK1, integrin-linked kinase (ILK),
DNA-PK, PKCα, PKCβ II, MK2, p38, NEK6, ATM and Akt itself have all been suggested
to mediate this phosphorylation event under particular contexts (10-13).

A third less characterized phosphorylation site on the tail region of Akt between the
kinase and hydrophobic motif domains is also important for Akt function. This phosphosite
(Thr450) is thought to either stabilize the active form of Akt through cooperation with S473
phosphosite (14) or interact with the catalytic region of Akt to promote folding and
stabilization (15). This tail/linker site, also called the turn motif (TM) phosphosite, requires
mTORC2 for phosphorylation (15, 16).

Activation of Akt is also facilitated by binding interactions of Akt with Hsp90 and Tcell leukemia 1 (TCL1). The heat shock protein Hsp90 binds to Akt and increases its activity
by preventing dephosphorylation by PP2A (17). TRB3 is a negative regulator of Akt that
binds Akt and blocks its activation (18). T-cell leukemia 1 (TCL1) acts as an Akt coactivator
that binds Akt to form oligomeric TCL1-Akt complexes, in which phosphorylation and
activation of Akt is enhanced (19, 20).
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Akt Inactivation

Akt is inactivated by dephosphorylation of its Thr308 and Ser473 residues by
general and specific phosphatases. PP1 and PP2A are general phosphatases that
dephosphorylate both the T308 and S473 sites (21-23). PHLPP1 and PHLPP2 are specific
phosphatases whose only known substrates are Akt and PKC (24). The PHLPP phosphatases
dephosphorylate only the hydrophobic motif site of its targets (Ser473 for Akt). Importantly,
PHLPP phosphatases demonstrate differential activities against different Akt isoforms
potentially contributing to the effects of the different isoforms (25).

Downregulation of PI3K/Akt Signaling

The major downregulator of PI3K/Akt signaling upstream of Akt is the PTEN
phosphatase, which catalyzes the dephosphorylation of PIP3 (3,4,5) to PIP2 (4,5), thus
reversing the reaction catalyzed by PI3K. Reduction of PIP3 (3,4,5,) levels in the cell
membrane inhibits recruitment of Akt to the cell membrane required for its optimal
activation.

Downregulation of Akt signaling also occurs through binding of carboxy terminal
modulator protein (CTMB) to the hydrophobic motif of Akt, preventing phosphorylation of
Akt on its Thr308 and Ser473 residues (26).

8

Akt Downstream Effects

Akt catalyzes the phosphorylation of numerous cellular proteins, with over 60 Akt
substrates reported in the literature to date. Through regulation of a multitude of downstream
signaling pathways that frequently interact with and amplify each other, Akt increases cell
proliferation, cellular metabolism, motility, cell growth, and cell survival. Cell proliferation
is increased through Akt’s actions on cell cycle regulators including GSK3, p27, and p21
(27). Akt activation of the mTOR pathway increases protein synthesis and cell growth (28).
Through regulation of the Bad, FoxO, Mdm2, IKK, and CREB pathways, Akt increases
transcription of anti-apoptotic factors and decreases transcription of pro-apoptotic factors
(29). These effects of Akt on cellular survival, growth, and proliferation in cancer cells
enable tumor progression. Akt also contributes to cell motility, invasion, and angiogenesis
(30, 31).

1.2

Aberrations of the PI3K/Akt Pathway in Cancer

Aberrations in the PI3K/Akt signaling network are prevalent in human cancers. Akt
mutations have been reported in human tumors but are rare occurrences (32-34).
Upregulated Akt signaling more often results from overexpression or amplification. Akt1
and Akt2 are overexpressed in colorectal cancer (35). Akt2 is amplified and overexpressed
in a subset of ovarian cancers (36, 37). Amplification and/or overexpression of Akt2 also
occur in a significant portion of head and neck squamous cell carcinomas (38), pancreatic
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cancer (39-41), and hepatocellular carcinoma (42). Akt3 is overexpressed in estrogen
receptor-negative breast cancers (43) and almost half of melanomas (44).

Whereas mutations of Akt are rarely observed, somatic missense mutations of the
PIK3CA gene encoding the alpha isoform of the PI3K catalytic subunit occur in 20-35% of
gastric (45), colorectal (45), glioblastoma (45), breast (46), liver (47), endometrial cancers
(48) and ovarian cancers of endometrioid and clear cell origin (49). Amplification of the
PIK3CA gene is a frequent event in breast (47), ovarian (50, 51), prostate (52), gastric (53),
cervical (54), thyroid (47), lung (55), and head and neck squamous cell cancers (38).

The regulatory subunit of PI3K is also frequently aberrant, with p85 amplification or
overexpression in most ovarian cancers (56) and mutation of p85 seen in glioblastoma,
colorectal, pancreatic cancers (57).

Loss of function of the PTEN phosphatase frequently occurs in human cancers and
results in constitutive activity of the PI3K/Akt pathway. Decreased PTEN function can
result from mutation, deletion, or promoter methylation as well as through post-translational
modification. PTEN alterations are seen in numerous tumor types including breast (58),
colorectal (59), gastric (60), cervical (61), glioblastoma (62), acute lymphoblastic leukemia
(ALL) (63), melanoma (64), prostate (52), endometrial (48), and ovarian cancers (65).

Activating mutations and amplifications of genes encoding receptor tyrosine kinase
(RTK) growth factor receptors result in constitutively upregulated signaling through the
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PI3K pathway. The HER2 RTK is amplified in several cancer types including breast (66),
ovary (67), stomach (68), and bladder (69) cancers. The RTK EGFR is amplified or
overexpressed in glioblastomas (70) and cancers of the breast (71), lung (72), and
colorectum (73). An activating EGFR (HER1) mutation is seen in high-grade gliomas (74),
glioblastomas (75) non-small cell lung cancer (NSCLC) (76), ovarian (77) , and breast
carcinomas (78). While the EGFR and HER2 RTKs are inefficient activators of PI3K
directly, they form heterodimers with HER3, which is a potent and efficient activator of
PI3K due to multiple p85 binding sites in its intracellular tail.

Since Ras can directly activate PI3K, activating mutations of Ras upregulate
PI3K/Akt pathway signaling. Ras mutations are present in almost all pancreatic
adenocarcinomas (79) as well as subsets of myeloid leukemias (80) and lung (81), ovarian
(82, 83), colorectal (84), and thyroid cancers (85).

1.3

Development of Akt Catalytic Domain Inhibitors as Anti-cancer Agents

The major importance of PI3K/Akt signaling has spurred development of numerous
potential therapeutics targeting components of the PI3K/Akt pathway (86). Included among
these drugs are Akt catalytic domain inhibitors as well as allosteric Akt inhibitors. Multiple
structurally distinct series of Akt catalytic domain inhibitors are in development, including
the indazole-pyridine based inhibitors from Abbott Laboratories (87) and the aminofurazanderived compounds developed by GlaxoSmithKline (88).
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Effects on the cancer phenotype of Akt catalytic domain inhibitors have been
evaluated in cancer cell lines, animal tumor models, and in clinical trials. The A443654 and
A674563 inhibitors from Abbott Laboratories effectively slowed proliferation of MiaPaCa-2
pancreatic cancer cells in culture and in a xenograft tumor model (87). 3T3-Akt1 xenografts
and a panel of glioblastoma multiforme cell lines showed increased apoptosis of tumor cells
with A443654 treatment, indicating anti-apoptotic effects may be one mechanism of slowed
tumor growth with this Akt inhibitor (87, 89). Local delivery of A443654 inhibited tumor
growth and extended survival in a rat model of intracranial glioma (89), indicating potential
therapeutic utility of A443654 and other Akt-targeting drugs in this disease. GSK690693,
the most well characterized Akt catalytic domain inhibitor from GlaxoSmithKline,
effectively inhibits proliferation of multiple cancer lines, including breast and prostate lines,
and was also found to induce apoptosis in vitro (88). In vivo tumor growth inhibition with
GSK690693 was demonstrated in xenograft models of ovarian, breast, and prostate cancer
(88).

Akt catalytic domain inhibitors have recently entered clinical trials
(http://www.clinicaltrials.gov). A phase I study of GSK690693 in solid tumors and
lymphoma was initiated but discontinued because of a serious adverse event. A phase I
study of GSK690693 in relapsed or refractory hematologic malignancies was subsequently
withdrawn. Exelixis conducted a Phase I study of XL418, a catalytic domain inhibitor of
both Akt and p70S6K, however this study was suspended due to low drug exposure.
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In spite of these challenges in clinical development, Akt catalytic domain inhibitors
demonstrate promise as potential anti-cancer therapeutics. Abbott and GlaxoSmithKline
continue to introduce additional chemical modifications to their Akt catalytic domain
inhibitors to produce compounds with more favorable pharmacological profiles (90-92).
GlaxoSmithKline is currently recruiting patients for Phase I trials of two follow-up
compounds - GSK2141795 and GSK21110183.

Phase I clinical trials of MK2206, an allosteric Akt inhibitor, have demonstrated
acceptable toxicity with both single agent and combination therapy trials underway for
multiple tumor types.

As these compounds are entering clinical trials, it is critical to understand their
mechanisms of action and on- and off-target activities both to increase the likelihood that
patients likely to benefit can be identified and to prevent unexpected patient toxicities.
Further, an understanding of mechanisms of action will facilitate the development of rational
combinatorial therapies.

1.4

Akt Inhibitor-induced Akt Phosphorylation

Strikingly, Akt catalytic domain inhibitors have been found to induce a paradoxical
increase in Akt phosphorylation on its Thr308 and Ser473 activation sites. Inhibitor-induced
Akt phosphorylation is characteristic of both the Abbott and GlaxoSmithKline Akt catalytic
domain inhibitors. Induction of Akt phosphorylation with A443674, a highly selective Akt
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inhibitor in the Abbott series, has been demonstrated in multiple cancer cell types (93) and
in vivo in a xenograft model of MiaPaCa-2-derived (pancreatic cell line) tumors (87). The
GSK690693 inhibitor from GlaxoSmithKline has also been shown to induce
phosphorylation of Akt in cell lines derived from multiple tumor types (88). Importantly,
although phosphorylation of Akt is normally associated with increased activity, in this case
the increased phosphorylation of Akt is not associated with Akt activation due to blockade
of the catalytic site by Akt inhibitor. Signaling mechanism(s) underlying induction of Akt
phosphorylation in response to treatment with Akt catalytic domain inhibitors have not been
well defined. This work reveals a role for Glycogen Synthase Kinase 3 (GSK3) in mediating
Akt inhibitor-induced phosphorylation.

1.5

GSK3 Function and Regulation

GSK3, originally discovered as a regulator of glycogen metabolism, has since been
found to interact broadly with multiple aspects of the signal transduction machinery of the
cell. Through its involvement in multiple pathways, GSK3 plays a role in both development
and disease processes, including Type II diabetes, inflammation, an array of neurological
disorders, and cancer.

GSK3 Structure and Isoforms

The GSK3 structure consists of an N-terminal region, kinase domain, and C-terminal
region. The two GSK3 isoforms GSK3α and GSK3β, encoded by different genes, are highly
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homologous in their kinase domains but are divergent in the N-terminus and C-terminus
regions. The N-terminus region of GSK3α but not GSK3β contains a glycine-rich domain
(94).

The GSK3α and GSK3β isoforms are not equivalent, as illustrated by GSK3
knockout mice. GSK3α knockout mice are viable (95), whereas GSK3β knockout mice
demonstrate massive liver apoptosis and die before birth (96). Mouse models have also
provided evidence that GSK3α regulates glycogen metabolism in the liver, and GSK3β
controls response of skeletal muscle to insulin (97). While GSK3α and GSK3β carry out
distinct roles in tissue-specific glycogen metabolism, the two GSK3 isoforms appear to
demonstrate redundancy in other signaling functions. For example, either GSK3 isoform can
compensate for the absence of the other in GSK3 regulation of Wnt/β-catenin signaling (98).

Modes of Regulation of GSK3

GSK3 mediates numerous functions through its involvement in multiple signaling
pathways. GSK3 must be strictly regulated to allow specific downstream signaling effects in
response to signals upstream of GSK3. Inactivating and activation phosphorylation,
requirement for substrate priming, sequestration within protein complexes, and subcellular
localization mechanisms regulate GSK3 function. Critically, the regulatory processes must
ensure that GSK3 and the functions it regulates are not under homeostatic control, being
activated in the appropriate contexts and returning to baseline after removal of the stimulus.
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Phosphorylation

GSK3 is a constitutively active enzyme regulated by inactivation. Kinase activity is
inhibited by phosphorylation on its Ser21/9 (GSK3α/GSK3β) residue within the N-terminal
region. Inhibitory phosphorylation can be mediated by Akt (99), as well as PKA (100),
atypical PKC (100), p90RSK (100), and ILK (101) as well as potentially by other kinases.

GSK3 also contains a tyrosine phosphorylation site at Tyr279/216 (GSK3α/GSK3β).
This site is constitutively phosphorylated and contributes to maximal activation of the
kinase. The mechanism regulating the phosporylation of GSK3 on the Tyr279/216 site is
controversial and still not well understood. The mechanism of tyrosine phosphorylation has
been suggested to be an autophosphorylation event (102), but has also been suggested to
occur through action of a separate kinase rather through an autoregulatory mechanism (103).

Substrate Priming

Most GSK3 substrates require prior phosphorylation by another kinase for efficient
phosphorylaton by GSK3. Priming phosphorylation generates the sequence Ser/Thr-X-X-XSer/Thr-PO4, which GSK3 phosphorylates on the first Ser/Thr residue (104, 105).
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Sequestration and Subcellular Localization

GSK3 is involved in multiple pathways. The formation of protein complexes such as
the GSK3 protein complex downstream of Wnt signaling is believed to sequester GSK3,
preventing regulation of GSK3 by other pathways. For example, inactivation of GSK3 by
Akt does not increase β-catenin levels (106). However, crosstalk between the Wnt and Erk
pathways has been described (107), and Erk interaction with GSK3 results in increased βcatenin (108), indicating the model of GSK3 sequestration may not be complete under
different cellular contexts and stimuli.

GSK3, like many other kinases, functions in different contexts as a kinase and as a
linker molecule. That is, some of the functions of GSK3 required its kinase activity, whereas
others are dependent on its ability to bind to other cellular components independent of its
kinase activity. In many cases, deconvoluting the two activities of GSK3 has been complex
and may represent independent or integrative contributions from both functions.

GSK3 can be localized to the cytosol, nucleus, or mitochondria. Subcellular
localization of GSK3 is an important regulatory mechanism that controls the availability of
upstream and downstream mediators of GSK3 pathways. For example, stimulation of the
intrinsic apoptotic signaling pathway with the DNA damaging agent camptothecin increases
activity of the nuclear and mitochondrial pools of GSK3, but does not increase activity of
GSK3 in the cytosol (109). The level of GSK3 in the nucleus varies during the cell cycle,
and is regulated by nuclear export of GSK3 bound to other proteins and by a nuclear
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localization sequence (NLS) motif of GSK3 (110). The role of GSK3 in these different
locations in the cell remains to be fully elucidated.

1.6

GSK3 Signaling in Cancer

GSK3 in Wnt Signaling

Signaling by the Wnt family of ligands regulates stem cell function, cellular polarity,
differentiation, and migration during development. GSK3 is a major component of the
canonical Wnt signaling pathway that regulates β-catenin-mediated transcriptional events.
Phosphorylation of β-catenin by GSK3 targets β-catenin for ubiquitinylation and
degradation. In the absence of downregulation by GSK3, β-catenin accumulates and binds to
TCF/LEF transcription factors to upregulate transcription of target genes, which promote
tumorigenesis and invasiveness of cancer cells (111). GSK3 phosphorylation of β-catenin
requires assembly of a protein complex known as the β-catenin destruction complex that
consists of GSK3, β-catenin, Axin, and adenomatous polyposis coli (APC). Binding of Wnt
ligand to its membrane-bound receptor disrupts the destruction complex and allows βcatenin to upregulate transcription of its targets.

Wnt also activates the mTOR pathway that plays important roles in regulating cell
growth and bioenergetics. After priming by other kinases, GSK3 provides an activating
phosphorylation for TSC2, a negative regulator of mTOR signaling. Wnt represses negative
regulation of mTOR by GSK3 through a mechanism that involves axin and APC (112).
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GSK3 in Hedgehog Signaling

Similar to the Wnt signaling pathway, binding of the secreted ligand Hedgehog (Hh)
to its transmembrane receptor Patched (Ptch) results in disruption of a complex in which
GSK3 directs proteolytic cleavage of Cubitus interruptus (Ci) protein. In the absence of
cleavage to a shorter, repressor form, which is dependent on GSK3, Ci induces expression of
Hh target genes. Germline mutations and sporadic mutations of the tumor suppressor Ptch
leads to increased incidence of basal cell carcinoma and medulloblastoma (113, 114).

GSK3 in Growth Factor Signaling

Growth factors such as epidermal growth factor (EGF) and insulin-like growth factor
(IGF) bind to their cell membrane receptors, leading to activation of Akt. Akt then
phosphorylates GSK3 on its Ser21/Ser9 (GSK3α/GSK3β) residue, resulting in an inactive
conformation of GSK3. Inhibition of GSK3 through Akt and other kinases as indicated
above, promotes cell cycle progression since the active form of GSK3 phosphorylates and
increases the proteosomal degradation rate of key cell cycle proteins including cyclin D1
(115), cyclin E (116), c-myc (117, 118), and p21 (119, 120).

GSK3 in JNK Signaling

GSK3 also interacts with the c-Jun N-terminal kinase (JNK) and p38 pathways,
which activate downstream oncogenic transcription factors. JNK and p38 are preferentially
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activated through stress stimuli, but can also be activated in response to growth factors (121)
and Wnt (122, 123). GSK3 binds to and inhibits the MEKK4 kinase, preventing activation
of downstream JNK and p38 (124). GSK3 also directly phosphorylates the JNK-activated cJun transcription factor on its Thr239 residue, targeting the oncogenic transcription factor
for ubiquitination and proteosomal degradation (125).

GSK3 and Apoptosis

GSK3 promotes the intrinsic apoptosis pathway mediated by mitochondrial
disruption and inhibits the extrinsic apoptosis pathway activated by death receptors (126).
Intrinsic apoptosis signaling is promoted by direct interaction of GSK3 with pro-apoptotic
and anti-apoptotic factors and regulation of transcription and translation factors that
modulate expression of apoptotic signaling molecules. GSK3 phosphorylates and activates
the pro-apoptotic Bcl-2 family member Bax (127) and phosphorylates and enhances the
degradation of anti-apoptotic Bcl-2 family member MCL-1 (128). The p53 transcription
factor is a key mediator of apoptosis. GSK3 has been shown to both physically modify p53
through phosphorylation (129) and promote its acetylation (130) through a binding
interaction with the C-terminal basic domain of p53 (130-132), contributing to the apoptotic
actions of p53 (131, 132). GSK3 inhibits protein translation through inhibitory
phosphorylation of the translation initiation factor eIF2B (133), affecting mitochondrial
cytochrome c release (134).
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GSK3 inhibits the extrinsic apoptosis pathway mediated by death-domain containing
receptors. GSK3 forms an anti-apoptotic complex with ddx3 and cIAP-1 near death
receptors to prevent formation of the death-inducing signaling complex (135).

Regulation of NF-KB by GSK3 has been shown to either promote or inhibit
apoptosis. These paradoxical observations result from NF-KB’s ability to influence both
intrinsic and extrinsic apoptotic signaling, and from variations of the role of NF-KB in
different cell and signaling contexts (126).

1.6

Overview of Dissertation

We demonstrate that phosphorylation of Akt on its activation sites in response to cell
treatment with Akt catalytic domain inhibitors or the EGF and IGF1 growth factors is
regulated by GSK3 in the MDAMB231 breast cancer cell line and in mouse embryonic
fibroblasts (MEFs). Additionally, we observed GSK3 dependence of basal Akt
phosphorylation in the AU565 breast cancer cell line. This work establishes a novel role of
GSK3 upstream of Akt in the PI3K/Akt pathway. The positioning of the effects of GSK3
both upstream and downstream of Akt raises important theoretical questions in terms of
pathway homeostasis and offers important new information related to the activity of the
PI3K pathway that are in or about to enter clinical trials.
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CHAPTER 2: MATERIALS AND METTHODS

2.1

Antibodies

Rabbit polyclonal antibodies to phospho-S6RP (Ser235/236), phospho-S6RP
(Ser240/244), phospho-Akt (Thr308), phospho-Akt (Ser473), Akt, rictor, raptor, p110α,
phospho-GSK3 (Ser21/9), phospho-p70S6K (Thr389), and phospho-β-catenin
(Ser33/37/Thr41) were purchased from Cell Signaling Technology (Danvers, MA). Rabbit
polyclonal antibodies to phospho-PRAS40 (Thr246) and p85 and mouse monoclonal
antibody to phosphotyrosine were purchased from Millipore (Billerica, MA). Mouse
monoclonal antibody to PRAS40 (Clone 73P21) was purchased from MBL Intl Corp
(Woburn, MA). Rabbit monoclonal antibodies to p110β (Clone Y384) and p110γ (Clone
Y388) were purchased from Epitomics (Burlingame, CA). Mouse monoclonal antibody to
GSK3 (Clone 1H8) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Mouse monoclonal antibody to GAPDH (Clone 6C5) was purchased from Ambion (Austin,
TX). HRP-conjugated goat anti-rabbit secondary antibody and HRP-conjugated goat antimouse secondary antibody were purchased from Bio-Rad (Hercules, CA). The antibodies
used in the RPPA study have been described previously (136).

2.2

Cell Lines

Tumor cell lines MDAMB231, A431, DU145, MDAMB468, SKOV3, AU565, T47D,
MCF7, MDAMB415, BT549, SKBR3, and OVCAR3 were cultured in RPMI 1640 medium
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supplemented with 5% fetal bovine serum (FBS). Mouse embryonic fibroblasts (MEFs)
were cultured in DMEM medium supplemented with 5% FBS. All cells were maintained at
37 °C with 5% CO2.

2.3

Small Molecule Inhibitors, Growth Factors, and Cell Treatments

The A674563 and A443654 Akt inhibitors were obtained through collaboration with
Abbott Laboratories (Abbott Park, IL). QLT0454 was obtained through collaboration with
QLT Incorporated. Rapamycin was purchased from Cell Signaling Technology. The GSK3
inhibitor SB216763 GSK3 inhibitor was purchased from Sigma (St. Louis, MO). LY294002
was purchased from Calbiochem (San Diego, CA). Epidermal growth factor (EGF) was
purchased from R&D Systems (Minneapolis, MN). Insulin-like growth factor 1 (IGF-1) was
purchased from Millipore (Billerica, MA). Cells were treated with the chemical inhibitors
for the indicated times after serum-starvation overnight (16 to 24 hours) unless otherwise
indicated.

2.4

siRNAs and Transient Transfection

siRNAs targeting rictor (pooled siRNA M-016984-00), raptor (pooled siRNA M004107-00), p110α (pooled siRNA M-003018-01), human GSK3α (pooled siRNA L003009-00), human GSK3β (pooled siRNA L-003010-00), mouse GSK3α (pooled siRNA
L-059026-00), mouse GSK3β (pooled siRNA L-041080-00), and nontargeted RISC-Free
control siRNA were purchased from Dharmacon (Lafayette, CO). Pan-GSK3 siRNA #1
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(siRNA 42839) was purchased from Ambion (Austin, TX). Pan-GSK3 siRNA #2 was
purchased from Cell Signaling Technology (Danvers, MA). Cells were plated 24 hours prior
to transfection at 40%-50% confluence. siRNAs were transfected using DharmaFECT
(Dharmacon) according to the manufacturer’s instructions. The culture medium was
changed 24 hours after transfection, and cells were serum-starved 48 hours post-transfection.
After overnight (16 to 24 hours) serum-starvation, cells were treated with inhibitors as
indicated and then harvested.

2.5

Cell Lysis and Western Blotting

After cell treatment with various inhibitors, cell culture dishes were placed on ice;
cells were washed twice with ice-cold phosphate-buffered saline and lysed in ice-cold lysis
buffer (1% Triton X-100, 50 mM Hepes, pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 1 mM
EGTA, 100 mM NaF, 10 mM sodium pyrophosphate, 1 mM Na3VO4, 10% glycerol, 1 mM
phenylmethylsulfonyl fluoride, and 10 µg/mL aprotinin). Cell lysates were collected after
centrifugation at 13,000 rpm for 10 minutes. The cellular protein concentration was
determined by BCA reaction with reagents from Pierce (Rockford, IL). The proteins in the
cell lysates were separated by SDS-PAGE and transferred to polyvinylidene difluoride
(PVDF) membranes. The membranes were blocked with 5% bovine serum albumin (BSA)
in TBS-T (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20) for one hour at room
temperature and then incubated overnight with antibodies diluted in 5% BSA in TBS-T:
anti-phospho-S6RP (Ser235/236) (1:1000 dilution), anti-phospho-S6RP (Ser240/244)
(1:1000 dilution), anti-phospho-Akt (Thr308) (1:1000 dilution), anti-phospho-Akt (Ser473)
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(1:1000 dilution), anti-Akt (1:1000 dilution), anti-rictor (1:1000 dilution), anti-raptor
(1:1000 dilution), anti-p110α (1:1000 dilution), anti-phospho-GSK3 (Ser21/9) (1:1000
dilution), anti-phospho-p70S6K (Thr389) (1:1000 dilution), anti-phospho-β-catenin
(Ser33/37/Thr41) (1:1000 dilution), anti-phospho-PRAS40 (Thr246) (1:1000 dilution), antiPRAS40 (Clone 73P21) (1:500 dilution), anti-p110β (Clone Y384) (1:500 dilution), antip110γ (Clone Y388) (1:1000 dilution), anti-GSK3 (Clone 1H8) (1:400 dilution), and antiGAPDH (Clone 6C5) (1:3000 dilution). The membranes were washed in TBS-T and
incubated with HRP-conjugated goat anti-rabbit secondary antibody (1:2500 dilution) or
HRP-conjugated goat anti-mouse secondary antibody (1:2500 dilution) for one hour at room
temperature. The membranes were washed with TBS-T and the proteins were visualized
using ECL from Amersham Bioscences (Piscataway, NJ).

2.6

p85 Immunoprecipitation

For immunoprecipitation of p85, cell lysates were incubated with anti-p85 for 90
minutes. Immune complexes were captured by incubation with G-conjugated Sepharose
beads for 90 minutes. Immunoprecipitates were washed three times with
immunoprecipitation buffer (0.5% Triton X-100, 0.5% Nonidet P-40, 10 mM Tris-HCl, pH
7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM Na3VO4, and 1 mM
phenylmethylsulfonyl fluoride), washed once with Tris-buffered saline, and boiled in 2X
SDS buffer before electrophoresis on SDS-PAGE gel.
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2.7

Reverse Phase Protein Array (RPPA)

Serial dilutions of cell lysate are spotted onto nitrocellulose-coated slides using an
Aushon Biosystems 2470 Arrayer. Each slide is stained for a different antibody using a
BioGenex Autostainer and a Dako amplification kit. Slides are scanned to provide images
for densitometry measurement by MicroVigene microarray image analysis software. For
each sample, the relative signal intensities for each antibody are quantitated using a
“SuperCurve” method, which fits all data onto a common curve and maps each sample data
point onto the curve. Each slide contains positive and negative controls to ensure quality of
slide printing and analysis. Each antibody has been validated for RPPA through correlation
of western blot results with RPPA analysis and measurement of the RPPA signal dynamic
range.
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GSK3 REGULATES AKT INHIBITOR-INDUCED AKT PHOSPHORYLATION

3.1

Introduction

As a result of the importance of the PI3K/Akt pathway in contributing to the
pathogenesis of human cancers, multiple potential inhibitors targeting molecules in this
signaling network are under preclinical assessment with a number of potential therapeutics
in early clinical trials. Both Akt catalytic domain and allosteric inhibitors are currently in
development as anti-cancer therapeutics. Strikingly, inhibition of Akt kinase activity with
Akt catalytic domain inhibitors results in a marked increase in phosphorylation on its
Thr308 and Ser473 activation sites. This observation has been reported with at least three
structurally distinct Akt catalytic domain inhibitors demonstrating hyperphosphorylation of
Akt in multiple cancer cell lines. Thus understanding the underlying mechanisms and
functional consequences of this process is of both theoretical and clinical relevance.

Akt inhibitor-induced phosphorylation of Akt has been demonstrated to be
dependent on PI3K and mTORC2, known upstream regulators of physiologic Akt
phosphorylation. It has also been demonstrated that Akt inhibitor-induced Akt
phosphorylation signaling is not due to the well-known negative feedback signaling loop in
which rapamycin analogs that inhibit mTORC1 induce IRS1-mediated phosphorylation of
Akt. In a recent paper by Okuzumi et al., the authors proposed a model of intramolecular
structural change of Akt upon inhibitor binding that renders Akt either more sensitive to
phosphorylation or more resistant to dephosphorylation (137). Thus catalytic Akt inhibitors
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can be used as probes of the mechanisms regulating Akt phosphorylation and
dephosphorylation in a system where downstream targets of Akt are not activated and where
the known mTORC1 mediated feedback loop is not activated. This isolation of upstream
processes regulating Akt from the downstream signaling events may allow the identification
of novel pathway regulators. Based on this opportunity as well as the need to understand the
mechanism involved and possible consequences to facilitate implementation of Akt
inhibitors into clinical trials, we decided to elucidate the underlying mechanisms responsible
for Akt phosphorylation.

In the present study, we utilize siRNAs and small molecule inhibitors to target
molecules in the PI3K/Akt signaling network to elucidate the molecular mediators of Akt
catalytic inhibitor-induced Akt phosphorylation. Here we report the dependence of Akt
inhibitor-induced Akt signaling on GSK3. GSK3 is a well-known downstream substrate of
Akt. To our knowledge, this is the first report of a role of GSK3 acting as a positive
upstream regulator of Akt.

3.2

Results

3.2.1

Treatment of multiple cancer cell lines with competitive reversible Akt

inhibitors induces phosphorylation of Akt on its activation sites.

Three competitive reversible inhibitors of Akt catalytic activity that compete at the
ATP binding site (87, 88, 93) have been demonstrated to increase phosphorylation. The Akt
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inhibitors A674563 and A443654, generated by Abbott Laboratories, and GSK690693,
produced by GlaxoSmithKline, result in inhibition of Akt activity as demonstrated by in
vitro kinase assays with GSK3β as substrate and decreased phosphorylation of Akt
substrates in cultured human cancer cell lines. Inhibition of Akt kinase activity with these
small molecule inhibitors is accompanied by increased phosphorylation of Akt on its
activation sites (Thr308 and Ser473) – phosphorylation events that would result in increased
activity of Akt were it not competitively inhibited by binding of the inhibitors to the ATP
binding site of Akt.

To study the mechanism by which inhibition of Akt increases Akt phosphorylation,
we determined the effect of three structurally distinct Akt inhibitors, the A674563 and
A443654 inhibitors produced by Abbott Laboratories and a third inhibitor QLT0454
produced by QLT Inc., on phosphorylation of the Thr308 and Ser473 sites of Akt in the
MDAMB231 breast cancer cell line (Figure 3.1A). All three inhibitors increase both
pThr308 and pSer473 in serum-starved (Figure 3.1A) as well as serum-replete cells (not
presented). The increase in phosphorylation of Akt was associated with inhibition of
downstream phosphorylation of PRAS40 and S6 Ribosomal Protein (S6RP) indicating
inhibition of Akt catalytic activity. The modest increase in total Akt levels likely reflects
decreased reactivity of the total Akt antibody used with phosphorylated Akt, an effect
observed in multiple studies. For subsequent experiments, the A674563 inhibitor was used.
In addition to the MDAMB231 breast cancer cell line, phosphorylation of Akt was induced
by A674563 in the A431 (epidermis), DU145 (prostate), MDAMB468 (breast), and SKOV3
(ovary) human cancer cell lines (Figure 3.1B). All cell lines tested with the catalytic domain
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Figure 3.1 Competitive reversible Akt inhibitors induce phosphorylation of
Akt in multiple cancer cell lines. A. MDAMB231 cells were serum-starved
overnight and treated for 2 hours with DMSO (0.3%), LY294002 (20 uM), or one
of three Akt inhibitors – A674563 (20 uM), A443654 (10 uM), or QLT0454 (20
uM). Cell lysates were analyzed for phosphorylation of Akt (Thr308 and Ser473)
and S6RP (Ser235/236 and Ser240/244) by immunoblotting. Effect on PRAS40
phosphorylation (Thr246) of A674563 was also analyzed. GAPDH was used as a
loading control. B. A431, DU145, MDAMB468, and SKOV3 cancer cell lines
were serum-starved overnight and then treated with LY294002 (20 uM), A674563
(20 uM), or DMSO (0.3%) vehicle for 2 hours. Cell lysates were analyzed for
phosphorylation of Akt (Thr308 and Ser473) and S6RP (Ser235/236 and
Ser240/244). GAPDH was used as a loading control.
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Akt inhibitors demonstrated an increase in phospho-Akt. Cell lines demonstrating Akt
inhibitor-induced phosphorylation and not presented here include BT549 (breast), SKBR3
(breast), and OVCAR3 (ovary). These cell lines demonstrate multiple genomic aberrations
including PTEN mutation, HER2 amplification, p53 mutation, and PIK3R1 mutations
demonstrating that the process occurs in the presence of multiple genomic aberrations. No
cell line was tested where the Akt catalytic domain inhibitors failed to induce increases in
Akt phosphorylation. Thus Akt inhibitor-induced Akt phosphorylation is likely due to ontarget effects and is generalizable across cellular lineages.

3.2.2

Akt catalytic domain inhibitor treatment is associated with increased signaling

upstream of Akt.

Akt is activated downstream of multiple receptor tyrosine kinase growth factor
receptors. The SH2 domains of p85, the regulatory subunit of PI3K, bind specific
phosphotyrosine residues of the activated growth factor receptor, inducing an activating
conformational change in the p110 catalytic subunit of PI3K and bringing it into proximity
of its phosphoinositide substrate. PI3K is also recruited to the membrane by p85 binding of
tyrosine-phosphorlated adaptor molecules complexed to an activated receptor tyrosine
kinase. To determine if catalytic domain Akt inhibitors induce changes in the PI3K/Akt
pathway upstream of Akt, we treated MDAMB231 cells with A674563, immunoprecipitated
p85α, and analyzed immunoprecipitates for tyrosine-phosphorylated proteins. A674563
induces increased tyrosine phosphorylation of a p85α-associated protein in the 90-110 kDa
size range (Figure 3.2), illustrating increased signaling in the PI3K/Akt pathway in response
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1.00 4.31

Figure 3.2 A674563 induces increased association of p85 with a tyrosinephosphorylated protein. MDAMB231 cells were serum-starved overnight and
treated for the indicated times with DMSO or A674563 (20 uM). p85 was
immunoprecipitated from cell lysates. Immunoprecipitates were probed for
phosphotyrosine and p85α by immunoblotting. Cell lysates were analyzed for pAkt
(Ser473), Akt, pS6RP (Ser240/244), and S6RP. Immunoprecipitation procedure was
performed by Dr. Yiling Lu.
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to Akt catalytic domain inhibitors. In a recent paper, a model was introduced in which Akt
hyperphosphorylation induced by Akt catalytic domain inhibitors results from a
conformational change in Akt upon inhibitor binding that renders Akt more sensitive to
activation by basal levels of signaling molecules upstream of Akt (137). However, our data
suggests that hyperphosphorylation of Akt in response to treatment with Akt catalytic
domain inhibitors is associated with an increase in upstream signaling, indicating that the
inhibitors may induce a feedback loop that increases upstream signaling rather than simply
rendering Akt more easily phosphorylated by upstream kinases.

3.2.3

A674563-induced Akt phosphorylation is inhibited by an allosteric PH domain

Akt inhibitor.

Physiological Akt activation is preceded by recruitment of Akt to the cell membrane
via binding of the PIP3 lipid to the PH domain of Akt. To determine if A674563-induced
Akt phosphorylation also requires Akt recruitment to the cell membrane, we pretreated
MDAMB231 cells with an allosteric Akt inhibitor, Akt Inhibitor VIII developed by Merck,
that locks Akt into an inactive conformation in which the PH domain is inaccessible to bind
PIP3 in the membrane (138). We pretreated cells with Akt Inhibitor VIII to prevent
membrane translocation of Akt before treating cells with the A674563 Akt catalytic domain
inhibitor. Results show abrogation of A674563-induced Akt phosphorylation with the
allosteric inhibitor pretreatment (Figure 3.3), indicating requirement of Akt membrane
translocation for this process. Importantly, phosphorylation of the Akt substrate PRAS40
was decreased, demonstrating effective Akt inhibition by Akt Inhibitor VIII and A674563.
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Figure 3.3 A674563-induced Akt phosphorylation is abrogated by treatment with an
allosteric PH domain Akt inhibitor. MDAMB231 cells were serum-starved overnight and
then treated with A674563 (20 uM for two hours) or preincubated with Akt Inhibitor VIII
(5uM) for 1 hour before 2-hour treatment with A674563. Cell lysates were analyzed for
phosphorylation of Akt (Thr308 and Ser473), Akt, and phosphorylation of PRAS40
(Thr246). GAPDH was used as a loading control.

35

3.2.4

Induction of Akt phosphorylation by A674563 is dependent on PI3K and

mTORC2 but not mTORC1.

PI3K-mediated production of PIP3 recruits Akt to the cell membrane through
binding of the Akt PH domain, facilitating phosphorylation and activation of Akt. To
determine if PI3K is required for the Akt phosphorylation induced with A674563, we
pretreated MDAMB231 cells with the PI3K inhibitor LY294002 prior to addition of
A674563. As shown in Figure 3.4A, induction of Akt phosphorylation by A674563 was
diminished in cells treated with LY294002. This result suggested that activity of PI3K is
required for the A674563-induced phosphorylation of Akt. However LY294002 inhibits
additional kinases including mTOR suggesting that other effects of LY294002 could explain,
at least in part, inhibition of Akt phosphorylation. To further investigate the requirement of
PI3K activity for A674563-induced Akt phosphorylation, expression of the p110α isoform
of the PI3K catalytic subunit was decreased using targeted siRNA (Figure 3.4B). The p110α
siRNA decreased p110α to undetectable levels without altering p110b or p110g levels. As
shown in Figure 3.4B, knockdown of p110α resulted in marked reduction in the level of Akt
phosphorylation induced with A674563 treatment. Since MDAMB231 cells express all three
class IA PI3K catalytic subunit isoforms (139), activity of the p110β and p110γ isoforms as
well as low levels of p110α, below detection by western blotting, remaining in the cells may
account for the residual Akt phosphorylation induced with A674563 under conditions of
p110α knockdown. The reduction in Akt phosphorylation induced by A674563-mediated
Akt inhibition in cells treated with pan-PI3K inhibitor LY294002 or p110α-targeted siRNA
demonstrates that PI3K activity is required to mediate the Akt phosphorylation induced by
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Figure 3.4 Induction of Akt phosphorylation by A674563 is dependent on PI3K. A.
MDAMB231 cells were serum-starved overnight, pretreated with LY294002 for 1 hour, and
then treated with A674563 for 2 hours. Cell lysates were a nalyzed for phosphorylation of
Akt (Thr308 and Ser473) by immunoblotting. GAPDH was used as a loading control. B.
MDAMB231 cells were transfected with either p110 -targeting siRNA or control
nontargeting siRNA. 48 h ours post-transfection, cells were serum-starved overnight and
then treated with A674563 or DMSO vehicle for 2 hours. Cell lysates were analyzed for Akt
phosphorylation (Thr308 and Ser473), p110 , p110 , and p110 . GAPDH was used as a
loading control.
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inhibition of Akt with A674563. Further, these results demonstrate that p110α is the PI3K
isoform mediating this process. As p110α is selectively activated as a consequence of
activation of cell surface tyrosine kinase-linked receptors whereas p110β is primarily
activated as a consequence of G protein coupled receptors (140), the selective effect of
targeting p110α is compatible with the contention that upstream activation of PI3K as a
consequence of p85 binding to tyrosine phosphorylated proteins plays a role.

The mTOR kinase forms two known protein complexes, mTORC1, the mTORraptor complex that functions downstream of Akt, and mTORC2, the mTOR-rictor complex
that has been demonstrated to phosphorylate Akt on its Ser473 activation site (9). The
requirement for mTOR-rictor in mediating Ser473 Akt phosphorylation that occurs in
response to A674563 treatment was investigated using rictor-targeted siRNA to prevent
formation of mTOR-rictor complex. As seen in Figure 3.5, rictor knockdown abrogates Akt
Ser473 phosphorylation in response to A674563 treatment. This result demonstrates the
dependence on mTOR-rictor for the increase in Ser473 Akt phosphorylation observed in
response to treatment with A674563.

Activation of mTOR-raptor, a downstream target of Akt, and its downstream target
p70S6K leads to degradation of IRS1 and subsequent decrease in Akt activation contributing
to homeostasis in the PI3K pathway. Inhibition of mTOR-raptor activity with rapamycin and
its analogs blocks this negative feedback signaling resulting in increased phosphorylation of
Akt. Increases in Akt phosphorylation levels generated by treatment with inhibitors of
mTOR-raptor have been demonstrated in human cancers and cell lines (141-144). The
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Figure 3.5 mTORC2 is required for A674563-induced phosphorylation of Akt on
its Ser473 site. MDAMB231 cells were transfected with either siRNA targeting rictor
or nontargeting control siRNA. 48 hours after transfection, cells were serum-starved
overnight and then treated with A674563 or DMSO vehicle for 2 hours. Cell lysates
were analyzed for Akt phosphorylation (Ser473) and rictor. GAPDH was used as a
loading control.
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increase in phosphorylated Akt levels resulting from treatment of cell lines with mTORraptor inhibitors is dependent on insulin-like growth factor signaling to IRS1 and requires
supplementation of cell culture medium with serum or insulin-like growth factor (IGF) (141,
142, 144). Since Akt catalytic domain inhibitors prevent Akt-dependent activation of
mTOR-raptor, we evaluated the possible role of mTOR-raptor inhibition in the A674563induced increase in phosphorylated Akt levels. As seen in Figure 3.6A, treatment of
MDAMB231 cells cultured in medium supplemented with fetal bovine serum (FBS) with
the mTOR inhibitor rapamycin induces a modest increase in phosphorylation of Akt on its
Thr308 and Ser473 activation sites. Effective inhibition of mTOR-raptor activity with
rapamycin is indicated by decreased phosphorylation of p70S6K on its Thr389 residue. In
comparison to the modest increases in Akt phosphorylation induced with rapamycin in
serum-supplemented cells, treatment with A674563 induced marked increases in Akt
phosphorylation on both activation sites. Treatment with rapamycin in MDAMB231 cells in
culture medium that has not been supplemented with FBS did not generate detectable
increase in Akt phosphorylation levels (Figure 3.6B). In contrast, the A674563-induced
increase in Akt phosphorylation was readily observed in serum-starved cells, indicating a
distinct mechanism of induction of Akt phosphorylation by the Akt catalytic domain
inhibitor.

The ability of A674563 to increase Akt phosphorylation was neither increased nor
decreased in cells pretreated with rapamycin (Figure 3.6A and 3.6B). Lack of effect of
inhibition of mTOR-raptor on A674563-induced phosphorylation of Akt indicates that
mTOR-raptor activity is not required for Akt inhibitor-induced Akt phosphorylation. To
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Figure 3.6 Akt phosphorylation induced by A674563 is not dependent on mTORC1. A.
MDAMB231 cells maintained in medium supplemented with 5% FBS were treated with
rapamycin for 3 hours, A674563 for 2 hours, or pretreated with rapamycin for 1 hour
followed by 2-hour A674563 treatment. Cell lysates were analyzed for phosphorylation of
Akt (Thr308 and Ser473) and p70S6K (Thr389). GAPDH was used as a loading control. B.
MDAMB231 cells were serum-starved overnight followed by 3-hour rapamycin treatment, 2hour A674563 treatment, or pretreated with rapamycin for 1 hour followed by 2-hour
A674563 treatment. Cell lysates were analyzed for phosphorylation of Akt (Thr308 and
Ser473) and p70S6K (Thr389). GAPDH was used as a loading control. C. MDAMB231 cells
were transfected with either raptor-targeting siRNA or control nontargeting siRNA. 48 hours
post-transfection, cells were serum-starved overnight and then treated with A674563 or
DMSO vehicle for 2 hours. Cell lysates were analyzed for Akt phosphorylation (Thr308 and
Ser473) and raptor. GAPDH was used as a loading control. The data presented is from a
single experiment and extraneous data was removed solely for clarity.
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further examine if there is any role for mTOR-raptor in induction of Akt phosphorylation by
A674563, we knocked down the expression of raptor with targeted siRNA in MDAMB231
cells and treated cells with A674563. Figure 3.6C shows that knocking down expression of
raptor does not interfere with A674563-induced Akt phosphorylation in serum-starved cells.

Taken together, these studies indicate that A674563-induced Akt phosphorylation
occurs independently of the mTOR-raptor signaling loop and does not require the activity of
mTOR-raptor.

3.2.5

Akt-inhibitor induced phosphorylation of Akt is dependent on GSK3.

In addition to mTOR-raptor, Akt phosphorylates numerous cellular signaling
proteins upon activation. Akt phosphorylates Glycogen Synthase Kinase 3 (GSK3) on its
Serine 21/9 (GSK3α/GSK3β) residue, inhibiting constitutive GSK3 downregulation cell
cycle progression.

We evaluated dependence of A674563-induced Akt phosphorylation on GSK3
utilizing targeted siRNA to knock down expression of the GSK3α and GSK3β isoforms
separately and in combination in MDAMB231 cells. Figure 3.7 illustrates that knockdown
of GSK3α or GSK3β modestly decreased Akt phosphorylation induced by A674563.
Knocking down expression of both the GSK3α and GSK3β isoforms resulted in marked
decrease in A674563-induced Akt phosphorylation (Figure 3.7). Thus, GSK3 is required for
Akt inhibitor-induced Akt phosphorylation and expression of both the GSK3α and GSK3β
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Figure 3.7 GSK3 is required for A674563-induced Akt phosphorylation in
MDAMB231 cells. MDAMB231 cells were transfected with siRNA targeting
GSK3α (50 nM), GSK3β (50 nM), or both isoforms of GSK3 (60 nM).
Nontargeting siRNA was used a control. 48 hours post-transfection, cells were
serum-starved overnight and then treated with A674563 (20 uM) or DMSO vehicle
(0.2%) for 2 hours. Cell lysates were analyzed for Akt phosphorylation (Thr308 and
Ser473) and GSK3 by immunoblotting. GAPDH was used as a loading control.
Densitometry measurements were calculated using version 1.38x of ImageJ.
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isoforms is required for maximum induction of Akt phosphorylation with A674563.

To determine if GSK3α and GSK3β are required for A674563 induction of Akt
phosphorylation in another mammalian system, we used wild type mouse embryonic
fibroblasts (MEFs) and GSK3β knockout MEFs. Knockdown of the individual GSK3
isoforms in the wild type MEFs yielded no significant decrease in A674563-induced Akt
phosphorylation, whereas knockdown of both isoforms markedly decreased phosphorylation
of Akt in response to A674563 treatment (Figure 3.8A). Similarly, knockdown of GSK3α in
GSK3β-/- MEFs yielded an almost complete loss of A674563-induced Akt phosphorylation
(Figure 3.8B). These results demonstrate the requirement for GSK3α and GSK3β in MEFs
to permit maximal induction of Akt phosphorylation in response to A674563 treatment.

3.2.6

A674563-induced Akt phosphorylation is independent of acute signaling effects

of GSK3 kinase activity.

GSK3 has two mechanisms of signaling – one through its kinase activity and a
second through its protein binding interactions. Abrogation of Akt inhibitor-induced Akt
phosphorylation by decreased expression of GSK3 may result from loss of GSK3 signaling
mediated by either its kinase activity or its protein binding interactions. Kinase activity of
GSK3 affects signaling pathways both through mediation of rapid
phosphorylation/dephosphorylation cascades and through phosphorylation events that alter
protein stability or protein expression.
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To investigate the role of acute signaling effects of GSK3 kinase activity in
regulating A674563-induced Akt phosphorylation, we preincubated MDAMB231 cells for
one hour with the pan-GSK3 kinase inhibitor SB216763 before exposing the cells to
A674563. As seen in Figure 3.9, inhibition of GSK3 kinase activity did not prevent
phosphorylation of Akt on its activation sites in response to treatment with A674563.
Importantly SB216763 effectively inhibited GSK3 activity as indicated by blockade of βcatenin phosphorylation. This result indicates independence of Akt inhibitor-induced Akt
phosphorylation on acute signaling effects mediated by the kinase activity of GSK3.

Effect of chronic inhibition of kinase activity of GSK3 on Akt inhibitor-induced Akt
phosphorylation was not tested due to limitations of our reagents. In MDAMB231 cells,
inhibition of GSK3 kinase activity by SB216763 (assayed by immunoblot of β-catenin
phosphorylation on the Ser33/37/Thr41 sites) lasts for less than six hours even with addition
of fresh inhibitor (data not presented).

Based on the independence of Akt inihibitor-induced phosphorylation on acute
effects of GSK3 kinase activity, observed abrogation of A674563-induced Akt
phosphorylation with knockdown of GSK3 expression for several days in the GSK3
knockdown studies may result from either the linker molecule function of GSK3 or from
chronic loss of GSK3 kinase activity.
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Figure 3.9 A674563-induced Akt phosphorylation is not dependent on acute
effects of GSK3 kinase activity. MDAMB231 cells were serum-starved
overnight, pretreated with SB216763 (10 uM) for 1 hour, and then treated with
A674563 (20 uM) for 2 hours. Cell lysates were analyzed for phosphorylation of
Akt (Thr308 and Ser473), β-catenin (Ser33/37/Thr41), and GSK3 (Ser21/9) by
immunoblotting. GAPDH was used as a loading control.
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3.2.7

GSK3 is not upstream of an A674563-induced p85-associated tyrosine

phosphoprotein.

To determine the role of GSK3 in the A674563 induction of tyrosine
phosphorylation of the p85-associated protein, expression of GSK3 was knocked down in
MDAMB321 cells using targeted pan-GSK3 siRNA prior to A674563 treatment and p85
immunoprecipitation. As seen in Figure 3.10, A674563 induction of tyrosine
phosphorylation of a protein in the 90-110 kDa size range is not decreased with GSK3
knockdown. This result suggests that if the A674563-induced tyrosine phosphoprotein is a
driver of Akt-inhibitor induced Akt phosphorylation, then the effect of GSK3 is downstream
of induction of tyrosine phosphorylation of this molecule and its association with p85 but
upstream of the phosphorylation of Akt. Further studies are warranted to determine the
identity and the role of the 90-110 kDa tyrosine phosphorylated protein in Akt inhibitorinduced Akt phosphorylation.

3.3

Discussion

The importance of the PI3K/Akt pathway in cancer is underscored by ongoing
development of an array of small molecule inhibitors directed against molecules in the
signaling network (86). Clinical trials of Akt inhibitors, including ATP competive kinase
inhibitors, allosteric inhibitors and phosphatidylinositidol analogs, are currently underway.
Evaluation of the global effects of Akt inhibition on PI3K signaling network have not been
fully elucidated and could alter the outcomes of patient treatment.
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Figure 3.10 A674563-induced tyrosine phosphorylation of a 85associated protein is independent of GSK3. MDAMB231 cells were
transfected with either pan-GSK3 siRNA (60 nM) or control
nontargeting siRNA. 48 hours post-transfection, cells were serumstarved overnight and then treated with A674563 or DMSO vehicle for 2
hours.
p85
was
immunoprecipitated
from
cell
lysates.
Immunoprecipitates were probed for phosphotyrosine and p85α by
immunoblotting. Cell lysates were analyzed for pAkt (Ser473), Akt,
pS6RP (Ser240/244), and S6RP. Immunoprecipitation procedure was
performed by Dr. Yiling Lu. Data from this experiment has been
presented in part earlier in this work (Figure 3.2).
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As demonstrated in the current work, the A674563 inhibitor induces a marked
increase in phosphorylation of Akt on its activation sites. As expected based on previous
studies with A443654, we show that induction of Akt phosphorylation with A674563 is
dependent on PI3K and mTORC2. The hyperphosphorylation of Akt in response to
A674563 treatment represents either an increase in the upstream signaling or a decrease in
the rate of Akt dephosphorylation once it has been phosphorylated by PDK1 and PDK2. Our
results show increased association of tyrosine-phosphorylated proteins with p85, the
catalytic subunit of PI3K, indicating increased signaling upstream of Akt.

We demonstrate the dependence on GSK3 of Akt inhibitor-induced Akt
phosphorylation. GSK3 has been known for more than a decade to be an important
downstream mediator of Akt signaling, however, this places GSK3 both upstream and
downstream of Akt. In both MDAMB231 breast cancer cells and MEFs, knocking down
GSK3 isoforms individually has only a modest effect on the ability of A674563 to induce
Akt phosphorylation, whereas knocking down both GSK3 isoforms yields a marked
decrease in A674563-induced Akt phosphorylation. These results may indicate the existence
of a pool of GSK3α and GSK3β mediating signaling to Akt. Depletion of either isoform
results in only a small decrease in A674563-induced Akt phosphorylation likely due to
incomplete compensation by the remaining isoform. In this model, knocking out both
isoforms of GSK3 markedly decreases the entire GSK3 pool abolishing A674563-induced
phosphorylation of Akt.
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GSK3 mediates its effects through both its kinase activity and through proteinprotein interactions. We did not observe dependence of Akt phosphorylation on GSK3
kinase activity. We did not test whether chronic inhibition of GSK3 diminishes Akt
inhibitor-induced Akt phosphorylation. Since GSK3 mediates some of it signaling effects
such as modification of gene transcription over longer periods than were tested in our
studies, there is still a possibility that the kinase function of GSK3 is involved in signaling
upstream of Akt phosphorylation. Alternatively, the linker molecule function of GSK3 may
be solely responsible for its upstream role regulating Akt phosphorylation. We did not detect
significant direct association of GSK3 with Akt itself (immunoprecipitation studies not
presented). Thus GSK3 may bind and regulate a protein involved directly or indirectly in the
processes of Akt phosphorylation or dephosphorylation.

The potential that GSK3 modulates a critical process or is physically positioned
upstream Akt signaling represents a novel signaling process that warrants further
investigation. Elucidation of the signaling mechanisms of Akt inhibitor-induced Akt
phosphorylation is necessary to allow prediction of local and global cellular response to
manipulation of specific pathway components and identification of valid therapeutic targets
and rational combinations of pharmacological treatments. Indeed, both catalytic and
allosteric Akt inhibitors are in clinical trials rendering this elucidation urgent.
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CHAPTER 4: GSK3 REGULATES GROWTH FACTOR SIGNALING TO AKT

4.1

Introduction

Dysregulation of EGFR or IGF1R signaling leads to constitutively upregulated
signaling through the PI3K/Akt and MAPK pathways and contributes to a variety of
malignancies. EGFR is mutated, amplified, or overexpressed in a subset of cancers. No
association of IGF1R mutations with cancer has been found, but IGF1R is overexpressed in
some cancer cell types (145). Anti-EGFR therapies are in clinical use for multiple cancer
types, and early-phase trials with anti-IGF1R therapies are underway. Development of
resistance is a significant challenge with growth factor receptor (GFR) targeted cancer
therapies. Frequently, activation of Akt signaling occurs through upregulation of alternate
upstream pathways (146). Significant crosstalk occurs between the EGFR and IGF1R
pathways, and subsequently tumors can acquire resistance to EGFR-targeted therapeutics
through compensatory upregulation of signaling through the IGF1R pathway (147).
Combination therapies targeting both EGFR and IGF1R or therapies targeting both a growth
factor receptor pathway and a signal downstream of the GFR may effect improved treatment
outcomes. Further elucidation of the signaling mechanisms regulating growth factor
signaling to Akt is warranted to provide potential molecular targets for cancer treatment.

Glycogen Synthase Kinase 3 (GSK3) functions in a variety of signaling pathways,
regulating important cellular functions such as cell polarity and glucose metabolism. GSK3
is constitutively active. However, Akt, as well as multiple other kinases, inhibits GSK3 by
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phosphorylation of its Ser 21/9 (GSK3β/GSK3α) residue. GSK3 has been proposed to
mediate many downstream effects of Akt by phosphorylation of cyclin D1 (115), cyclin E
(116), c-myc (117, 118), and p21 (119, 120).

We have discovered that GSK3 is also involved in signaling upstream of Akt. This
finding is novel and without precedence in the literature. Using targeted siRNAs to knock
down GSK3 expression, we show here that GSK3 mediates EGF- and IGF1-stimulated
activation of Akt in the MDAMB231 breast cancer cell line and in mouse embryonic
fibriblasts (MEFs). We also found GSK3 controls Akt phosphorylation independent of
growth factor stimulation in the HER2-positive AU565 breast cancer cell line. These
findings define GSK3 as a regulator of upstream signaling to Akt. Thus GSK3, similar to
multiple other components of the PI3K pathway, mediates critical up and downstream
events in the PI3K pathway.

4.2

Results

4.2.1

EGF- or IGF1-stimulated activation of Akt is dependent on GSK3 in the

MDAMB231 breast cancer cell line.

Activation of the PI3K/Akt pathway occurs in response to upstream activation of the
EGF and IGF growth factor signaling systems. Tyrosine phosphorylation of the GFR
recruits adaptor molecules to form a signaling complex at the cell membrane. Binding of the
SH2 domain of the p85 regulatory subunit of PI3K to specific phosphotyrosine residues of
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the GFR or linked adaptor molecules leads to activation of the p110 catalytic subunit of
PI3K and subsequent activation of Akt. Downregulation of GFR signaling occurs through
multiple mechanisms such as internalization and degradation of the growth factor receptor
or dephosphorylation of GFR tyrosine residues by members of the protein tyrosine
phosphatase (PTP) family.

To investigate whether GSK3 plays a role in the signaling from growth factors to
Akt, we determined the effects of GSK3 knockdown on the ability of EGF and IGF1 to
stimulate Akt phosphorylation in the MDMB231 breast cancer cell line (Figure 4.1A). As
seen in Figure 4.1A, knockdown of either the GSK3α or GSK3β isoforms with targeted
siRNAs effected little or no change in the level of Akt phosphorylation induced by
stimulation with either the EGF or IGF1 growth factor. Knockdown of expression of both
isoforms of GSK3 resulted in significant reduction in EGF- and IGF1-induced Akt
phosphorylation on both its Thr308 and Ser 473 activation sites (Figure 4.1A). Thus, GSK3
regulation of EGF and IGF1 signaling to Akt can be mediated by either isoform of GSK3.
To verify that the decrease in growth factor stimulated Akt phosphorylation corresponds to a
decrease in Akt activity, we determined the phosphorylation levels of the Akt substrate
PRAS40. As seen in Figure 4.1A, we found decreased levels of phosphorylated PRAS40
(Thr246) in response to growth factor stimulation in cells in which the expression of GSK3
had been knocked down using siRNA. These results demonstrate that Akt phosphorylation
and activation in response to the EGF and IGF1 growth factors is regulated by GSK3 in the
MDAMB231 breast cancer cell line. GSK3 dependence of EGF- and IGF1-stimulated Akt
phosphorylation was verified using an additional pan-GSK3 siRNA (Figure 4.1B).
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Figure 4.1 GSK3 regulates EGF- and IGF1-stimulated Akt phophorylation in the
MDAMB231 breast cancer cell line. MDAMB231 cells were tranfected with siRNA
targeting GSK3α, GSK3β, or both isoforms of GSK3. Nontargeting siRNA was used a
control. Cells were serum-starved overnight and then treated with EGF (60 ng/mL) or
IGF1 (50 ng/mL) for 20 minutes. Cell lysates were analyzed for Akt phosphorylation
(Thr308 and Ser473), PRAS40 phosphorylation (Thr246), and GSK3 by
immunoblotting. GAPDH was used as a loading control. B. An additional pan-GSK3
siRNA was tested for modulation of EGF- and IGF1-stimulated Akt phosphorylation.
Cell lysates were analyzed for Akt phosphorylation (Thr308 and Ser473) and GSK3 by
immunoblotting. GAPDH was used as a loading control.
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4.2.2

Akt phosphorylation is dependent on GSK3 in the AU565 breast cancer

cell line.

Since we discovered that EGF- and IGF1-stimulated activation of Akt is dependent
on GSK3 in the MDAMB213 breast cancer cell line, we screened additional breast cancer
cell lines to determine if GSK3 also regulates upstream signaling to Akt in these lines.
Figure 4.2 shows that knockdown of GSK3 with targeted siRNA decreased Akt
phosphorylation on both the Thr308 and Ser473 activation sites in the AU565 breast cancer
cell line. Akt phosphorylation in AU565 cells is not responsive to IGF1 stimulation. AU565
cells express high levels of HER2 and have basally high levels of phosphorylation of Akt.
As shown in Figure 4.2, GSK3 knockdown significantly decreased this basal level of Akt
phosphorylation. The finding that GSK3 is required for basal Akt phosphorylation in the
AU565 cell line demonstrates that GSK3 mediates signaling to Akt in multiple cell systems.
As in the MDAMB231 cell line, the GSK3α and GSK3β isoforms function redundantly in
controlling the phosphorylation of Akt, with significant decreases in Akt phosphorylation
seen only when expression of both GSK3 isoforms is knocked down. GSK3 knockdown
with targeted siRNA did not significantly decrease EGF- and IGF1-stimulated Akt
phosphorylation in the MDAMB415, MCF7, or T47D breast cancer cell lines (data not
presented). Taken together, these results indicate that the dependence on GSK3 of upstream
signaling to Akt is cell context dependent or alternatively, that residual GSK3 present in
these cells is sufficient to mediate signaling to Akt.
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Figure 4.2 GSK3 regulates Akt phosphorylation in the AU565 breast cancer
cell line. AU565 cells were transfected with siRNA targeting GSK3α, GSK3β, or
both isoforms of GSK3. Nontargeting siRNA was used a control. Cells were
serum-starved overnight and then treated with IGF1 (50 ng/mL) for 20 minutes.
Cell lysates were analyzed for Akt phosphorylation (Thr308 and Ser473), Akt, and
GSK3 by immunoblotting. GAPDH was used as a loading control.
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4.2.3

GSK3 regulates EGF and IGF1 signaling to Akt in Mouse Embryonic

Fibroblasts (MEFs).

To further assess the role of GSK3 in optimal growth factor signaling to Akt in
another mammalian system, we investigated EGF and IGF1 signaling in mouse embryonic
fibroblasts (MEFs). We first stimulated wildtype and GSK3 knockout MEFs with IGF1 and
determined effects on Akt phosphorylation by immunoblotting. Figure 4.3A illustrates no
effects of loss of individual GSK3 isoforms on IGF1-stimulated phosphorylation of Akt.

Since in the MDAMB231 and AU565 cancer cell lines knockdown of the expression
of both GSK3 isoforms was required to prevent Akt phosphorylation, we then investigated
whether decreased expression of both GSK3 isoforms decreases growth factor induced Akt
phosphorylation in MEFs. We utilized targeted siRNA to knock down expression of GSK3α
in GSK3β knockout MEFs and evaluated Akt phophosphorylation in response to stimulation
of cells with EGF or IGF1. Figure 4.3B shows that decreased expression of both the GSK3α
and GSK3β isoforms results in reduced ability of EGF to stimulate phosphorylation of Akt.
A modest decrease in IGF1-stimulated Akt phosphorylation was also observed (Figure
4.3B). These results demonstrate that GSK3 regulates phosphorylation of Akt in MEFs
induced by EGF and to a lesser degree, by IGF1.
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Figure 4.3 GSK3 mediates EGF and IGF1 signaling to Akt in Mouse Embryonic
Fibroblasts (MEFs). A. Wildtype mouse embryonal fibroblasts (MEFs) and GSK3β-/- and
GSK3α-/- MEFs knockouts were serum-starved overnight before stimulation with IGF1 for
the indicated times. Cell lysates were analyzed for Akt phosphorylation (Ser473) and GSK3
by immunoblotting. B. GSK3β knockout MEFs were transfected with GSK3α siRNA or
control nontargeting siRNA. 48 hours after transfection cells were serum-starved overnight
and then stimulated with EGF (60 ng/mL) or IGF1 (50 ng/mL). Cell lysates were analyzed
for Akt, Akt phosphorylation (Thr308 and Ser473), and GSK3α. GAPDH was used as a
loading control.
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4.2.4

Akt activation by EGF and IGF1 is independent of acute signaling effects of

GSK3 kinase activity.

GSK3 performs many of its signaling functions through substrate phosphorylation.
To determine if GSK3 regulation of growth factor signaling to Akt is mediated by GSK3
kinase function, we chemically inhibited GSK3 kinase activity and measured Akt
phosphorylation levels after stimulation of MDAMB231 cells with either EGF or IGF1. As
seen in Figure 4.4, pretreatment of cells with GSK3 inhibitor SB216763 did not prevent
EGF- or IGF1-induced Akt phosphorylation, indicating independence of Akt activation on
acute effects of GSK3 kinase activity.

Since GSK3 regulation of Akt phosphorylation is not dependent on the acutely
mediated effects of the kinase activity, remaining potential mechanisms of GSK3 regulation
of upstream signaling to Akt include 1) non-kinase effects of GSK3 (protein bindingmediated interactions) and 2) signaling downstream of GSK3 kinase activity that are
mediated over a longer timescale than we investigated in these studies.

4.2.5

GSK3 knockdown induces multiple changes in cell signaling.

To determine the effects of GSK3 on EGF and IGF1 signaling to a broad range of
signaling proteins, we knocked down expression of GSK3 using targeted siRNA in
MDAMB231 cells, stimulated cells with EGF or IGF1, and analyzed cell lysates by reverse
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Figure 4.4 EGF and IGF1-stimulated Akt phosphorylation are not dependent on acute
effects of GSK3 kinase activity. MDAMD231 cells were serum-starved overnight before
treatments with SB216763 (10 uM) and either EGF (60 ng/mL) or IGF1 (50 ng/mL). Cells
were treated for 1 hour with SB216763, 20 minutes with EGF or IGF1, or 1 hour with
SB216763 followed by 20 minutes stimulation with EGF or IGF1. Cell lysates were analyzed
for Akt, phospho-Akt (Thr308 and Ser473), phospho-B-catenin (Ser33/37/Thr41), and GSK3.
GAPDH was used as a loading control.
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phase protein array (RPPA) to measure the levels of 88 proteins and phospho-proteins in the
PI3K pathway and other cell signaling pathways. Figure 4.5 illustrates the cell signaling
profiles for the GSK3 knockdown experiments (results of two independent experiments are
displayed). Among the 88 signals measured, there are marked differences between the two
independent experiments for some proteins and phosphoproteins (i.e. Bcl-, ERK2,
Fibronectin, PCNA, Stat3, YAP, and others), which may reflect differences in cell culture
conditions or differences in handling of the lysate samples. Retesting of signaling changes of
these proteins is warranted. However, both experiments demonstrated effective knockdown
of GSK3 and expected concomitant decrease in EGF- and IGF1-induced Akt
phosphorylation (illustrated in Figure 4.6 for Eperiment #1).
GSK3 knockdown induced numerous additional cell signaling changes. Excluding
GSK3, phospho-GSK3, and phospho-Akt, the changes of greatest magnitude (≥ 2-fold
change compared to appropriate control) are listed in Figure 4.7. Signals exhibiting at least a
two-fold decrease with GSK3 knockdown for conditions of EGF stimulation, IGF1
stimulation, and no growth factor stimulation include total caveolin-1 levels and
phosphorylation (activation) of p70S6K pathway proteins. β-catenin level was the only
signal demonstrating at least a two-fold increase with GSK3 knockdown for all growth
factor stimulation conditions. YAP protein levels were also changed more than two-fold
with GSK3 knockdown for all growth factor stimulation conditions, but care must be taken
in interpreting the significance of the YAP signal changes as the changes were in opposite
directions for the two experiments (decreased YAP expression in Experiment #1 and
increased YAP expression in Experiment #2). Additional 2-fold changes were seen with
GSK3 knockdown in one or two of the three growth factor stimulation conditions. Bcl-2
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levels were changed more than 2-fold for conditions of EGF stimulation and no growth
factor stimulation. Changes in Bcl-2 levels with GSK3 knockdown were in opposite
directions for the two independent experiments (increased Bcl-2 expression in Experiment
#1 and decreased Bcl-2 expression in Experiment #2). GSK3 knockdown decreased
expression of Smad3 and VEGFR2 more than 2-fold under the condition of no growth factor
stimulation. Increased expression of Cox-2 with GSK3 knockdown was seen for the EGFstimulated condition, and increased level of phospho-ACC (Ser79) was seen for the IGF1stimulated condition. Changes for all signals induced by GSK3 knockdown under conditions
of EGF-stimulation, IGF1-stimulation, and no growth factor stimulation (averages and
values from each of the two independent experiments) are presented in Tables 1, 2, and 3
(found in the Appendix section), respectively.
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Experiment #1

Experiment #2
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Figure 4.5 GSK3 knockdown induces multiple cell signaling changes. MDAMB231 cells were transfected with either panGSK3 siRNA or control nontargeting siRNA. Cells were stimulated for 20 minutes with either EGF (60 ng/mL), IGF1 (100
ng/mL), or no growth factor. Cell lysates were processed on a reverse phase protein array (RPPA) and stained for antibodies to
each of the indicated proteins and phospho-proteins. RPPA procedure and initial data analysis performed by the Functional
Proteomics Reverse Phase Protein Array Core Facility.

Figure 4.6 Effective knockdown of GSK3 and decrease of Akt phosphorylation
with GSK3 siRNA transfection. Normalized linear values from RPPA analysis
(Experiment #1) are depicted for Akt phosphorylation (Thr308 and Ser473) and
GSK3.
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No Growth Factor Stimulation
Antibody
B-catenin*
Bcl-2*
Caveolin-1*
P-S6RP (S240/S244)*
Smad3*
VEGFR2*
YAP*

Average Fold Change (Exp #1 Fold
Change, Exp #2 Fold Change)
2.3 (2.9, 1.7)
±2.8 (3.4, -2.2)
-2.9 (-2.3, -3.5)
-5.3 (-4.7, -5.8)
-2.0 (-1.5, -2.4)
-2.2 (-1.7, -2.7)
±2.4 (-1.7, 3.0)

EGF Stimulation
Antibody
B-catenin*
Bcl-2*
Caveolin-1*
Cox-2**
P-p70S6K (T389)*
P-S6RP (S235/S236)*
P-S6RP (S240/S244)*
YAP*

Average Fold Change (Exp #1 Fold
Change, Exp #2 Fold Change)
2.4 (2.8, 2.0)
±2.0 (2.2, -1.8)
-4.0 (-4.0, -4.0)
2.0 (2.5, 1.5)
-2.4 (-2.1, -2.8)
-2.1 (-1.7, -2.6)
-6.1 (-5.2, -7.0)
±2.3 (-1.8, 2.8)

IGF1 Stimulation
Antibody
P-ACC (S79)*
B-catenin*
Caveolin-1*
P-S6RP (S240/S244)*
YAP*

Average Fold Change (Exp #1 Fold
Change, Exp #2 Fold Change)
2.2 (1.8, 2.6)
2.2 (2.4, 2.0)
-3.2 (-2.8, -3.6)
-4.0 (-4.2, -3.8)
±2.6 (-1.6, 3.7)

Figure 4.7 RPPA antibody signals showing at least 2-fold change in response to
GSK3 knockdown in MDAMB231 cells. Given fold change values are averaged from the
two independent experiments, and fold change values from each individual experiment are
included in parentheses. “Validated” antibodies, indicated by the “*” symbol, demonstrate
performance for RPPA comparable to an ELISA assay. “Use with Caution” antibodies,
indicated by the “**” symbol, provide high-quality useful information considered to need
confirmation by additional technology.
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4.3

Discussion

We have demonstrated here that GSK3 is required for optimal signaling upstream of
Akt. While knockdown of GSK3 in human and MEF cells markedly decreased
phosphorylation of Akt, this effect was not recapitulated by inhibition of GSK3 kinase
activity. Thus either GSK3 functions as a linker molecule or long term inhibiton of GSK3
kinase activity is required to reveal the function of GSK3 upstream of Akt.

GSK3 does not regulate signaling to Akt in all breast cancer cell lines. Differences in
genetic background may play a role in whether or not Akt signaling will be sensitive to
regulation by GSK3. The MDAMB231 breast cancer cell line that has CDKN2, p53, NF2,
Ras and Raf mutation and the AU565 cell line that exhibits HER2 amplification and PTEN
and p53 mutations demonstrated dependence on a GSK3 regulated event for optimal
signaling to Akt. MDAMB415 that has a p53 mutation, MCF7 that has a CDKN2 and a
helical domain PIK3CA mutation, and T47D that has catalytic domain PIK3CA and p53
mutations did not demonstrate dependence on GSK3 of Akt phosphorylation. The three cell
tested that did not exhibit dependence on GSK3 of Akt phosphorylation (MDAMD415,
MCF7, and T47D) all overexpress the estrogen receptor, which has been shown to activate
Akt (148), and may be the major driver of signaling to Akt in these lines. Further
investigation is required to characterize the cell context dependence of GSK3 regulation of
signaling to Akt.
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The RPPA approach allowed a screen of 88 proteins and phospho-proteins for
signaling changes in response to GSK3 knockdown. We identified a series of proteins that
showed marked changes in expression or phosphorylation status in response to GSK3
knockdown. Known mechanisms of modulation by GSK3 of these proteins and known
mechanisms for each protein in the regulation of Akt phosphorylation are described below.

Caveolin-1:
Caveolin is the primary structural component of caveolae, which are plasma
membrane microdomains containing large amounts of cholesterol and sphingolipids.
Caveolins contain a scaffolding domain which binds and concentrates a number of signaling
molecules including receptor tyrosine kinases (RTKs) and G-protein coupled receptors
(GPCRs). No known mechanism of GSK3 modulation of caveolin-1 expression is reported
in the literature. A significant body of literature does link expression of caveolin-1 to Akt
activation. Caveolin-1 inhibits PP2A and PP1, preventing these phosphatases from
dephosphorylation and inactivating Akt (149). In addition to inhibiting inactivation of Akt
by phosphatases, caveolin-1 is colocalized with IGF1R (150) and augments the activation of
Akt through IGF1 signaling. IGF1-stimulated phosphorylation of Akt has been shown to be
reduced with knockdown of caveolin-1 in PC12 cells (150) and in an MCF-7-derived cell
line (151). Similarly, Matthews et al. showed that IGF1-stimulated Akt phosphorylation was
reduced in caveolin-1 knockout MEFs (152). Caveolin-1 also increased EGF-stimulated Akt
phosphorylation in the MCF7 breast cancer cell line (153). Thus caveolin-1 is a strong
candidate to explain the effects of GSK3 knockdown on Akt signaling.
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p70S6K pathway:
GSK3 is known to inhibit the mTOR/p70S6K pathway through phosphorylation of
TSC2 (112). Based on this connectivity, we might have expected knockdown of GSK3 to
result in an increase in phosphorylation of p70S6K and subsequent increase in Akt
phosphorylation through IRS1-mediated feedback. However, our experimental results show
decreased phosphorylation of p70S6K and its substrate, S6 Ribosomal Protein (S6RP). No
published studies have proposed signaling mechanisms that would decrease phosphorylation
of p70S6K and S6RP in response to GSK3 knockdown, and decreased phosphorylation of
these proteins is not known to reduce Akt phosphorylation. Thus it is likely that the effect of
GSK3 knockdown on these proteins is through inhibiton of Akt activity.

β-catenin and Smad3:
GSK3 phosphorylation of β-catenin and Smad3 targets these proteins for degradation
(111, 154). Consequently, decreased expression of GSK3 results in accumulation of βcatenin and Smad3, as seen in our RPPA results. There are no known mechanisms for
modulation of Akt phosphorylation by β-catenin and Smad3.

YAP:
Akt and other kinases have been reported to phosphorylate YAP on its Ser127
residue, promoting YAP binding to 14-3-3 and cytoplasmic retention of the YAP/14-3-3
complex (155, 156). However, Akt is not reported to regulate expression levels of YAP.
YAP is not known to regulate signaling upstream of Akt, but YAP does interact with
membrane proteins including NHERF family members and HER4 (156), which are known
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to signal upstream of Akt. GSK3 knockdown was associated with markedly decreased
expression of YAP in Experiment #1 and dramatically increased YAP expression in
Experiment #2. Further experiments are needed to determine the significance of the changes
in YAP expression in the two experiments. YAP protein levels are known to be cell densitydependent (157), and this may account for some of the differences seen between the two
experiments.

Bcl-2:
GSK3 regulates function of NFkB and is known to affect transcription of NFkB
target genes, including Bcl-2 (158, 159). Based on both this known regulation of Bcl-2
expression by GSK3 and the known regulation of Bcl-2 by Akt (160), we expect knockdown
of GSK3 to result in the decreased Bcl-2 expresssion seen in Experiment #2. Further repeats
of the experiment are needed to determine the significance of the unexpected and marked
increase of Bcl-2 expression seen with GSK3 knockdown in Experiment #1. Bcl-2 has
recently been implicated in upstream regulation of Akt in a pancreatic cancer cell line (161),
and thus could potentially mediate GSK3 regulation of upstream Akt signaling.

VEGFR2:
VEGFR2 is a tyrosine kinase-containing member of the VEGFR family of receptors.
Although studied mainly in the context of neovascularization, VEGF receptors are expressed
on cancer cells. Caution needs to be used in interpretation of the VEGFR2 results as
although the antibody is reported to be specific by the manufacturer, others in our laboratory
have not been able to confirm this result and it likely interacts with multiple VEGFR
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isoforms. Downregulation of VEGFR2 by GSK3 has not been noted previously. Further,
none of the known effects of GSK3 would be predicted to decrease VEGFR2 levels. On the
contrary, GSK3β has been shown to decrease ability of kallikrein, a peptidase important in
vasodilation and angiogenesis, to induce VEGFR2 mRNA expression levels in myocardial
cells (162). VEGFR2 is a known upstream activator of Akt signaling (163), and thus,
decreased VEGFR2 expression with GSK3 knockdown may result in concomitant decrease
in Akt phosphorylation. Further evaluation of VEGFR2 as a potential intermediate in GSK3
signaling upstream of Akt is warranted.

Cox-2:
Cox-2 catalyzes the formation of pro-inflammatory prostaglandins. GSK3 is not
known to modulate Cox-2 expression, and Cox-2 is not known to inhibit Akt
phosphorylation. On the contrary, the inhibition of Cox-2 has been reported to inhibit
phosphorylation of Akt (164, 165).

P-ACC (Ser79):
Phosphorylation of acetyl-CoA carboxylase (ACC), an important enzyme in fatty
acid synthesis, on its Ser79 residue by AMPK inhibits ACC activity. GSK3 is not known to
regulate ACC phosphorylation, and ACC activity is not known to regulate Akt
phosphorylation. However, there is marked crosstalk between the Akt and AMPK pathway
through the ability of Akt to upregulate glucose uptake and bioenergetics. Indeed, the
increase in pACC levels is likely to reflect this effect in the MDAMB231 cells.
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Decreased expression of caveolin-1 associated with GSK3 knockdown for all growth
factor conditions tested provides a potential mechanism for GSK3 regulation of Akt
phosphorylation. Alternatively, GSK3 regulation of Akt could be mediated by proteins
exhibiting less than a two-fold change in signal intensity with GSK3 knockdown, proteins
not currently known to affect Akt, or proteins not assayed in this experiment. Additional
studies are required to elucidate in further detail the mechanism of GSK3 regulation of Akt
phosphorylation.

Further studies elucidating the molecular events in GSK3 regulation of signaling
upstream of Akt will define novel signaling interactions in the PI3K/Akt pathway and may
identify potential molecular targets for anti-cancer therapy.
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CHAPTER 5: DISCUSSION

In this work we have described a novel role for GSK3 in signaling upstream of Akt.
Specifically, we have demonstrated that GSK3 functions in the pathways of signaling to Akt
mediated by three separate ligands – Akt catalytic domain inhibitors, epidermal growth
factor (EGF), and insulin-like growth factor-1 (IGF1).

5.1

Models of Akt Catalytic Domain Inhibitor-induced Akt Phosphorylation

Currently two models have been described in the literature that have the potential to
explain the increase in Akt phosphorylation that occurs with treatment of Akt catalytic
domain inhibitors. In the first model, phosphorylation of Akt induced by Akt catalytic
domain inhibitors is independent of decreased Akt substrate phosphorylation. In this model,
inhibitor binding alters the interaction of the catalytic domain with other regions of Akt,
resulting in stronger affinity for PIP3 of the Akt PH domain and increased susceptibility of
the Thr308 and Ser473 sites to phosphorylation and/or decreased susceptibility to
dephosphorylation by phosphatases (137). In the second model, upregulated phosphorylation
of Akt results from disruption of a homeostatic negative feedback signaling loop that adjusts
upstream signaling to Akt based on level of Akt activity towards its downstream substrates
(93). The two models of increased Akt phosphorylation of Akt induced by Akt catalytic
domain inhibitors are illustrated in Figure 5.1.
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Figure 5.1. Two possible mechanisms of induction of Akt phosphorylation with
catalytic domain Akt inhibitors. A. Pathway-independent model of intrinsic Akt kinase
alteration by inhibitor binding to Akt catalytic domain. B. Feedback signaling model of
Akt inhibitor-induced Akt phosphorylation.
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The pathway-independent model of Akt inhibitor-induced Akt phosphorylation is
based on studies of a mutant Akt, asAkt (analog sensitive Akt), with a modified ATPbinding pocket. To abolish any off-target signaling effects of the Akt inhibitor, an A443654derived catalytic domain inhibitor, PrINZ, was developed that selectively binds to the asAkt
mutant (137). Treatment of cells with PrINZ induces phosphorylation of Thr308 and Ser473
sites of asAkt mutant molecules but not wildtype Akt. This finding argues against an
activation of signaling upstream of Akt, which would likely lead to phosphorylation of both
endogeneous Akt and asAkt.

However, we have provided evidence in this work of stimulation by A674563 of
signaling upstream of Akt. Specifically, we demonstrated increased tyrosine
phosphorylation of a p85-associated protein in response to cell treatment with A674563. The
identity of this p85-associated tyrosine-phosphorylated protein has not yet been determined.
Potential candidates, listed in Table 1, include proteins containing a p85-binding motif (pYxxM) in the 90-110 kDa molecular weight range. The most likely candidates for identity of
this protein will be determined by mass spectrometry analysis of the p-85-associated
tyrosine phosphoprotein Western blot band that is induced by A674563 treatment. We have
not yet investigated whether induction of p85-associated tyrosine phosphorylation is driving
the increase in Akt phosphorylation, this but induction of tyrosine phosphorylation clearly
shows that Akt catalytic domain inhibitors induce signaling changes other than alteration of
Akt intramolecular structure. Dependence of Akt inhibitor-induced Akt phosphorylation on
physiologic upstream regulators of Akt as reported in the literature and demonstrated in our
work is consistent with both the kinase intrinsic and pathway-dependent models.
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Table 4. List of 90-110 kDa proteins containing the p85-binding motif sequence.
Candidate proteins were identified using the “Site Search” advanced search interface of
PhosphoSitePlus (www.phosphosite.org), a manually curated phosphorylation site database.
Protein abbreviations are included in the List of Abbreviations on pages xv-xix.
Protein

p85-Binding Motif
Tyrosine Phosphosite

p85-Binding Motif Sequence

AFAP-110
AP1G1
AP2B1

Y54
Y55
Y276
Y737
Y534
Y779
Y821
Y263
Y419
Y444
Y459
Y371
Y731
Y363
Y713
Y723
Y296
Y321
Y881
Y226
Y628
Y824
Y730
Y721
Y900
Y562
Y214
Y250
Y526
Y554
Y754
Y181
Y324
Y36
Y163
Y113
Y8
Y213
Y305
Y655
Y798
Y800
Y63

SSSSDEEyIYMNKVT
RNVAKLLyMHMLGYP
LLPKDSDyYNMLLKK
THRQGHIyMEMNFTN
MDSYSGPyGDMRLET
ADCLDGLyALMSRCW
QEPDEILyVNMDEGG
CETVISYyTDMEEIG
GEEADAVyESMAHLS
PGCDEDLyESMAAFV
PAATEDLyVEMLQAS
TQEQYELyCEMGSTF
QQIDSCTyEAMYNIQ
TQEQYELyCEMGSTF
EASAFSYyGVMALTA
SSQGVDTyVEMRPVS
MGYDDLDyGMMSDYG
PRRRLRSyEDMIGEE
PACPQGLyELMLRCW
IINQEGEyIKMFMRG
AGEFGEVyKGMLKTS
SEDGSDPyVRMYLLP
SNCTNELyMMMRDCW
CSDSTNEyMDMKPGV
EHAPAEMyDIMKTCW
FKESLRPyDVMDVIE
RSQESGYyDRMDYED
YHKFDSEyERMGRGP
PYGKIKNyILMRMKS
RLHPNPMyQRMPLLL
DHFSRKDyQRMLDLM
QRNIKKEyAKMVQVL
EKNVLSQyWTMGSRN
NRSRDHDyRDMDYRS
ESDSLLDySCMQRLG
VWVDEMNyYDMRTDR
MEELQDDyEDMMEEN
NRLKVLFyRGMLDHI
RELDNLQyRKMKKIL
HDNIVTHyKNMIREQ
VVGSLSQyQLMKHQS
RVCPKEVyDVMLGCW
PNSEGGLyVCMNTFL

AR
Axl
BCAP

Cbl
Cbl-b
CNNM2
CSFR
CTNND1
DDR1
EML4
EphA2
ESYT2
FGFR1
Kit
Kv7.2
Matrin 3

MuSK
PDE2A
PMS2
PTPN3
RBM10
RTF
Sec5
SLC4A1
SLITRK3
TAO3
TAP
TLR5
TrkC
USP13
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5.2

GSK3 Mediation of Akt Inhibitor-induced Akt Phosphorylation

This work demonstrates dependence on GSK3 of Akt inhibitor-induced Akt
phosphorylation. Knockdown of GSK3 expression prevented A674563-induced
phosphorylation of Akt in the MDAMB231 breast cancer cell line and in mouse embryonic
fibroblasts. However, GSK3 dependence of Akt-inhibitor induced Akt phosphorylation was
not tested in other cell lines so it is unclear whether GSK3 is required for the increased
phosphorylation of Akt in the multiple cell lines where we and others have demonstrated
that Akt inhibitors increase Akt phosphorylation. Knockdown of both the GSK3α and
GSK3β isoforms is required for significant decrease of Akt inhibitor-induced Akt
phosphorylation, indicating redundance of the two isoforms in mediating this signaling
function.

Requirement of GSK3 for induction of Akt phosphorylation indicates that GSK3
positively regulates an activator of Akt phosphorylation or negatively regulates a
downregulator of Akt phosphorylation. Possible proteins GSK3 may modulate include
regulatory binding partners of Akt or one of the numerous kinases or phosphatases in the
PI3K/Akt signaling network. As demonstrated in Chapter 4, knockdown of GSK3 alters
levels and phosphorylation of many different proteins. Thus, knockdown of GSK3
modulates functions of many proteins and deconvoluting those that are required for the
effect of GSK3 knockdown is likely to prove challenging. The effect of complete
knockdown of GSK3 on multiple signaling pathways is not surprising given that concurrent
knockout of both GSK3α and GSK3β is embryonic lethal.
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Since GSK3 functions as both a kinase and protein binding partner (linker molecule),
effects of GSK3 on Akt phosphorylation may be mediated by either the kinase or linker
molecule function of GSK3. Our studies showed no effect on A674563-induced Akt
phosphorylation of preincubation of cells with GSK3 kinase inhibitor, indicating GSK3
kinase function is not required to mediate the phosphorylation of Akt. However, in addition
to mediating rapid phosphorylation/dephosphorylation signaling cascades, GSK3
phosphorylates several proteins that modify activity of transcription factors, resulting in
further changes in cell signaling after a period of several hours required to alter target gene
expression. The observed abrogation of A674563-induced Akt phosphorylation with
knockdown of GSK3 expression for several days may result from either the physical linker
function of GSK3 or from chronic loss of GSK3 kinase activity.

GSK3 is a known substrate of Akt, with Akt inactivating the constitutive GSK3
kinase through serine phosphorylation. GSK3 mediation of Akt inhibitor-induced
phosphorylation of Akt may result from two separate signaling functions of GSK3 upstream
and downstream of Akt. Alternatively, GSK3 may serve as a downstream sensor of Akt
kinase activity and mediate a feedback signaling loop to regulate upstream phosphorylation
of Akt. The model of GSK3 as a sensor of Akt activity provides a potential mechanism of
Akt inhibitor-induced Akt phosphorylation. In this model, inhibition of Akt decreases
phosphorylation of GSK3, leading to accumulation of unphosphorylated GSK3, which
upregulates upstream signaling to Akt. This potential mechanism is illustrated in Figure 5.2.
Other potential downstream sensors of the proposed feedback loop include any of the many
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Akt Catalytic Domain Inhibitor
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Figure 5.2. Potential mechanism of Akt feedback signaling through GSK3.
Inhibition of Akt kinase activity leads to accumulation of unphosphorylated GSK3,
which increases upstream signaling to increase levels of phosphorylated Akt.
Increased font size indicates increased amount of molecule. Increased arrow
thickness indicates greater signaling intensity.
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proteins downstream of Akt. We have tested for mediation of Akt inhibitor-induced
feedback signaling by the Akt downstream signaling kinases JNK1/2 (data not presented)
and by the Akt downstream signaling protein complex mTORC1.

5.3

GSK3 Regulation of Signaling from EGF and IGF1 to Akt

In addition to GSK3 playing a role in Akt-inhibitor induced Akt phosphorylation, we
have discovered a role of GSK3 in regulating stimulation of Akt in response to the
endogenous growth factors EGF and IGF1. The general pathway of signaling from EGF and
IGF1 to Akt is known. EGF or IGF1 activate their respective tyrosine kinase receptors,
leading to binding of signaling proteins to receptor phosphotyrosine residues. Participation
of the regulatory subunit of PI3K in protein complexes (EGFR-Grb2-Gab1-PI3K and
IGF1R-IRS-PI3K) formed by the growth factor receptor and adaptor molecules results in
activation of PI3K and downstream Akt (166, 167). EGFR also heterodimerizes with other
members of the EGFR family and in particular HER3 that contains multiple p85 binding
motifs (168). Decreased EGF- and IGF1-stimulated Akt phosphorylation observed in our
studies with knockdown of GSK3 expression in MDAMB231 breast cancer cells and mouse
embryonic fibroblasts reveals a previously uncharacterized signaling event in these
pathways. The observed decrease of the basally high levels of phosphorylated Akt with
GSK3 knockdown in the AU565 breast cancer cell line likely indicates dependence on
GSK3 of signaling to Akt from a constitutively active overexpressed HER2 receptor in this
cell line. Since the HER2 receptor is known to dimerize with EGFR and other EGFR family
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receptors (169), this result may represent GSK3 regulation of signaling to Akt downstream
of HER2 homodimers or heterodimers of HER2 with other receptors in the EGFR family.

Regulation of EGF- and IGF-stimulated Akt phosphorylation by GSK3 was observed
in only a subset of the cell lines tested, indicating cell context dependence of this signaling
mechanism. GSK3 knockdown with targeted siRNA did not significantly decrease EGF- and
IGF1-stimulated Akt phosphorylation in the MDAMB415, MCF7, or T47D breast cancer
cell lines (data not presented). Screening a larger panel of cell lines will be necessary to
reveal which cell characteristics determine sensitivity of EGF and IGF- stimulated Akt
phosphorylation on GSK3 modulation.

As with GSK3 playing a role in Akt inhibitor-induced Akt phosphorylation, EGFand IGF1-stimulated phosphorylation of Akt were not significantly affected by knockdown
of individual GSK3 isoforms while knockdown of both the GSK3α and GSK3β isoforms
markedly decreased induction of Akt phosphorylation by EGF and IGF1. Regulation of
EGF- and IGF1-stimulated Akt phosphorylation by GSK3 was also independent of shortterm GSK3 kinase signaling events. It is possible that regulation by GSK3 of both
EGF/IGF1-stimulated and Akt inhibitor-induced Akt phosphorylation are mediated by the
same mechanism.

In an effort to detect proteins or phosphoproteins that may be responsible for the
effect of GSK3 on Akt phosphorylation, we screened multiple cell signaling pathways in
unstimulated and EGF- or IGF1-stimulated MDAMB231 cells for changes associated with
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decreased GSK3 expression. Knockdown of GSK3 yielded changes in expression or
phosphorylation level of numerous proteins, including decreased expression of Caveolin-1, a
known upstream activator of Akt. Regulation of expression of Caveolin-1 provides a
potential mechanism by which GSK3 could alter ligand induced Akt phosphorylation.

5.4

Future Directions

Further studies are required to determine the signaling events by which Akt catalytic
domain inhibitors increase Akt phosphorylation and the roles of GSK3 inhibitor-induced and
EGF/IGF1-stimulated Akt phosphorylation.

Measurement of PIP3 lipid from lysates of cells treated with Akt catalytic domain
inhibitors and comparison with basal levels will inform us whether or not the Akt inhibitors
increase PI3K activity and induce accumulation of phosphatidylinositols. An increase in
PIP3 levels with Akt inhibitor treatment would support the feedback signaling model of Akt
inhibitor-induced Akt phosphorylation and would in turn direct our studies to evaluate
potential molecules involved in Akt feedback signaling. Identification through mass
spectrometry of the tyrosine phosphoprotein induced by A674563 treatment would enable
siRNA-targeted knock down of its expression and assessment of any role of this protein in
Akt inhibitor-induced Akt phosphorylation. The existence of a feedback loop would require
a molecular sensor of changes in Akt kinase activity that communicates with upstream Akt
signaling molecules. We would need to determine if GSK3 mediates this sensor function.
Overexpression of GSK3 in MDAMB231 cells will aid our studies of GSK3 regulation of
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Akt phosphorylation. An increase in phosphorylation of Akt in response to overexpression
of GSK3 would indicate that GSK3 is not merely serving a permissive role in signaling
upstream of Akt but is sufficient to drive phosphorylation of Akt.

We need to evaluate long-term signaling effects of the GSK3 kinase function in
GSK3 regulation of Akt inhibitor-induced and EGF/IGF1-stimulated Akt phosphorylation.
In MDAMB231 cells, inhibition of GSK3 kinase activity by SB216763 (assayed by
immunoblot of β-catenin phosphorylation on the Ser33/37/Thr41 sites) lasts for less than six
hours even with addition of fresh inhibitor (data not presented). Therefore, we could not
study long-term GSK3 kinase inhibition with this reagent. Additional chemical inhibitors of
GSK3 kinase activity need to be evaluated for use in long-term inhibition studies.
Alternatively, we may employ GSK3β-Y216F MEFs that produce a mutant GSK3β with
markedly decreased kinase activity for these studies.

Multiple growth factors such as FGF (fibroblast growth factor) and PDGF (plateletderived growth factor) are known to activate Akt signaling. GSK3 dependence of signaling
to Akt from growth factors other than EGF and IGF1 needs to be tested to determine the
scope of the role of GSK3 in upstream Akt signaling. Importantly, we would need to
determine why GSK3 knockdown in some lines but not others blocks signaling to Akt.
Indeed, a detailed RPPA study comparing the effects of GSK3 knockdown in lines where
GSK3 is required to induce optimal Akt phosphorylation to those where GSK3 is not
required could identify potential candidates. This screen could be further improved by
comparing the effects of GSK3α and GSK3β siRNA alone, which are insufficient to block
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Akt phosphorylation with the pan-GSK3 siRNA that efficiently blocks Akt activation. This
could be extended further by comparison to the effect of inhibition of GSK3 kinase activity
with a chemical inhibitor that does not decrease ligand-induced increase of Akt
phosphorylation.

While we have identified GSK3 as an upstream regulator of Akt activation, we have
not determined the precise placement of GSK3 in the signaling pathway. Determining if
knock down of GSK3 prevents the massive increases in levels of PIP3 known to occur with
EGF and IGF1 stimulation will inform us if GSK3 signals upstream or downstream of this
event. However, the demonstration that tyrosine phosphorylation of a protein that associates
with p85 induced by Akt catalytic domain inhibition occurs despite GSK3 knockdown
argues that the effect of GSK3 knockdown is distal to receptor activation and proximal to
Akt phosphorylation. The recruitment of p85 to phosphotyrosine-containing molecules also
argues that the effect of GSK3 knockdown is distal to p85 and PI3K activation.

Decreased expression of Caveolin-1, a known upstream activator of Akt, was
correlated with GSK3 knockdown. Knockdown of Caveolin-1 expression using targeted
siRNAs and measurement of Akt phosphorylation in response to EGF and IGF1 stimulation
will reveal if Caveolin-1 is activating signaling to Akt downstream of EGF and IGF1.
Positive results would then be followed up by overexpression studies to determine if
Caveolin-1 is downstream of GSK3 in the Akt signaling pathway.
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5.5

Concluding Remarks

Inhibition of signaling pathways upstream of Akt represents a major strategy being
evaluated for control of cancers dependent on the PI3K/Akt signaling pathway. Therapies
targeting EGF and IGF1 signaling are in the clinic, and Akt catalytic domain inhibitors are
in clinical trials. Discovery of a novel function of GSK3 in mediating signal from these
ligands to Akt may improve understanding and anticipation of drug effects. Further
elucidation of the molecular events mediating GSK3 control of signaling to Akt may
identify additional druggable targets in the pathway and facilitate development of more
effective cancer therapeutic strategies.
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APPENDIX

Table 1. Changes in expression levels and phosphorylation status in response to GSK3
knockdown in MDAMB231 cells.
Table 2. Changes in expression levels and phosphorylation status in EGF-treated
MDAMB231 cells in response to GSK3 knockdown.
Table 3. Changes in expression levels and phosphorylation status in IGF1-treated
MDAMB231 cells in response to GSK3 knockdown.
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Table 1. Changes in expression levels and phosphorylation status in response to GSK3
knockdown in MDAMB231 cells. Given fold change values are averaged from the two
independent experiments, and fold change values from each individual experiment are
included in parentheses. “Validated” antibodies, indicated by the “*” symbol, demonstrate
performance for RPPA comparable to an ELISA assay. “Use with Caution” antibodies,
indicated by the “**” symbol, provide high-quality useful information considered to need
confirmation by additional technology.
Antibody
14-3-3 Beta*
14-3-3 Zeta*
P-4EBP1 (S37)*
P-4EBP1 (S65)*
P-4EBP1 (T70)**
4EBP1*
P-ACC (S79)*
AIB-1*
P-Akt (T308)*
P-Akt (S473)*
Akt*
P-AMPK (T172)*
AMPK**
Androgen Receptor*
P-B-catenin (S33/S37/T41)**
B-catenin*
BCL2*
BIM*
P-c-Jun (S73)**
c-Kit*
c-Myc**
Caspase 3**
Caspase 7**
Caveolin-1*
CD31*
Collagen VI*
Cox-2**
c-Raf*
Cyclin B1*
Cyclin D1*
Cyclin E1*
E-cadherin*
P-EGFR (Y992)*
P-ER alpha (S118)*
ETV6**
FAK**
Fibronectin**
FoxO3**
P-FoxO3 (S318)**
GATA3*
P-GSK3 (S21/9)*

Average Fold Change (Exp #1 Fold
Change, Exp #2 Fold Change)
-1.3 (-1.1, -1.5)
1.2 (1.4, 1.0)
-1.4 (-1.8, -1.1)
-1.4 (-1.3, -1.5)
-1.1 (-1.1, -1.1)
1.1 (1.1, 1.1)
1.9 (1.6, 2.2)
1.2 (1.3, 1.0)
±1.2 (-1.1, 1.2)
-1.4 (-1.5, -1.2)
-1.3 (-1.3, -1.2)
1.4 (1.0, 1.8)
±1.3 (1.2, -1.3)
-1.5 (-1.3, -1.6)
1.5 (1.5, 1.4)
2.3 (2.9, 1.7)
±2.8 (3.4, -2.2)
1.0 (1.1, 1.0)
1.7 (1.7, 1.7)
1.0 (1.0, 1.0)
1.2 (1.3, 1.0)
1.1 (1.0, 1.3)
±1.1 (1.1, -1.1)
-2.9 (-2.3, -3.5)
±1.5 (-1.3, 1.7)
1.1 (1.1, 1.1)
±1.5 (1.8, -1.1)
1.6 (1.3, 1.8)
1.7 (1.5, 1.9)
-1.2 (-1.1, -1.2)
-1.1 (-1.0, -1.1)
1.8 (1.0, 2.6)
±1.3 (-1.2, 1.5)
±1.2 (1.2, -1.1)
-1.8 (-1.9, -1.6)
1.2 (1.0, 1.3)
1.6 (1.0, 2.1)
1.0 (1.0, 1.0)
-1.2 (-1.2, -1.2)
1.0 (1.0, 1.1)
-4.4 (-4.7, -4.1)
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GSK3*
P-HER2 (Y1248)*
Hsp27**
IGFBP2*
IGFR1 beta**
IRS1*
JNK2**
P-MAPK (T202)*
P-MEK1/2 (S217)*
MEK1*
MGMT*
P-mTOR (S2448)*
mTOR*
N-Cadherin*
p21**
p27*
p38**
p53*
P-p70S6K (T389)*
p70S6K*
PI3K p85*
P-p90RSK (T359)**
PARP**
P-PDK1 (S241)*
PDK1*
P-PKC alpha (S657)*
PKC alpha*
Progesterone Receptor*
Patched**
PTEN*
Rab25**
P-Rb (S807)*
Rb*
P-S6RP (S235/S236)*
P-S6RP (S240/S244)*
Smad3*
P-Src (Y527)*
Src*
P-STAT3 (Y705)*
Stathmin*
Tau**
TAZ*
TSC2**
VASP**
VEGFR2*
XIAP**
YAP*

-11.1 (-9.7, -12.5)
-1.4 (-1.2, -1.7)
1.3 (1.4, 1.3)
±1.1 (-1.1, 1.1)
-1.2 (-1.1, -1.3)
±1.1 (-1.2, 1.1)
1.3 (1.2, 1.3)
1.3 (1.6, 1.0)
1.5 (1.5, 1.5)
1.4 (1.5, 1.3)
1.2 (1.1, 1.3)
1.3 (1.1, 1.5)
1.1 (1.1, 1.2)
-1.1 (-1.0, -1.1)
±1.4 (1.5, -1.2)
1.2 (1.3, 1.1)
±1.2 (1.1, -1.3)
1.1 (1.1, 1.2)
-1.3 (-1.3, -1.4)
1.4 (1.3, 1.5)
-1.0 (-1.1, -1.0)
1.2 (1.1, 1.3)
1.4 (1.1, 1.7)
-1.4 (-1.4, -1.4)
-1.1 (-1.2, -1.0)
-1.2 (-1.4, -1.0)
-1.3 (-1.3, -1.4)
1.0 (1.0, 1.0)
-1.4 (-1.4, -1.5)
1.1 (1.1, 1.1)
1.0 (1.0, 1.1)
1.2 (1.1, 1.3)
±1.3 (1.3, -1.3)
-1.7 (-1.7, -1.7)
-5.3 (-4.7, -5.8)
-2.0 (-1.5, -2.4)
-1.3 (-1.3, -1.2)
-1.3 (-1.3, -1.4)
-1.1 (-1.2, -1.0)
-1.1 (-1.1, -1.2)
1.0 (1.0, 1.1)
1.4 (1.0, 1.8)
1.5 (1.2, 1.8)
±1.2 (1.2, -1.2)
-2.2 (-1.7, -2.7)
1.1 (1.0, 1.1)
±2.4 (-1.7, 3.0)
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Table 2. Changes in expression levels and phosphorylation status in EGF-treated
MDAMB231 cells in response to GSK3 knockdown. Given fold change values are
averaged from the two independent experiments, and fold change values from each
individual experiment are included in parentheses. “Validated” antibodies, indicated by the
“*” symbol, demonstrate performance for RPPA comparable to an ELISA assay. “Use with
Caution” antibodies, indicated by the “**” symbol, provide high-quality useful information
considered to need confirmation by additional technology.
Antibody
14-3-3 Beta*
14-3-3 Zeta*
P-4EBP1 (S37)*
P-4EBP1 (S65)*
P-4EBP1 (T70)**
4EBP1*
P-ACC (S79)*
AIB-1*
P-Akt (T308)*
P-Akt (S473)*
Akt*
P-AMPK (T172)*
AMPK**
Androgen Receptor*
P-B-catenin (S33/S37/T41)**
B-catenin*
BCL2*
BIM*
P-c-Jun (S73)**
c-Kit*
c-Myc**
Caspase 3**
Caspase 7**
Caveolin-1*
CD31*
Collagen VI*
Cox-2**
c-Raf*
Cyclin B1*
Cyclin D1*
Cyclin E1*
E-cadherin*
P-EGFR (Y992)*
P-ER alpha (S118)*
ETV6**
FAK**
Fibronectin**
FoxO3**
P-FoxO3 (S318)**
GATA3*
P-GSK3 (S21/9)*

Average Fold Change (Exp #1 Fold
Change, Exp #2 Fold Change)
-1.2 (-1.2, -1.3)
-1.0 (-1.1, -1.0)
±1.4 (-1.8, 1,1)
-1.4 (-1.4, -1.4)
-1.1 (-1.1, -1.10
1.2 (1.2, 1.2)
1.6 (1.4, 1.8)
1.1 (1.2, 1.1)
-1.8 (-1.9, -1.8)
-10.1 (-11.5, -8.7)
-1.2 (-1.2, -1.3)
1.2 (1.1, 1.3)
1.2 (1.2, 1.1)
-1.3 (-1.3, -1.2)
1.3 (1.4, 1.2)
2.4 (2.8, 2.0)
±2.0 (2.2, -1.8)
1.1 (1.0, 1.2)
1.7 (1.9, 1.5)
1.1 (1.0, 1.2)
±1.0 (1.0, -1.1)
±1.1 (-1.1, 1.1)
±1.2 (1.3, -1.1)
-4.0 (-4.0, -4.0)
1.1 (1.1, 1.1)
-1.1 (-1.1, -1.0)
2.0 (2.5, 1.5)
1.4 (1.2, 1.6)
1.9 (1.6, 2.2)
-1.4 (-1.3, -1.5)
-1.2 (-1.2, -1.1)
1.0 (1.0, 1.0)
1.4 (1.0, 1.8)
1.2 (1.3, 1.1)
-1.2 (-1.1, -1.4)
1.0 (1.0, 1.0)
1.7 (1.1, 2.3)
1.1 (1.1, 1.0)
1.1 (1.0, 1.1)
1.3 (1.3, 1.2)
-6.8 (-6.8, -6.8)
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GSK3*
P-HER2 (Y1248)*
Hsp27**
IGFBP2*
IGFR1 beta**
IRS1*
JNK2**
P-MAPK (T202)*
P-MEK1/2 (S217)*
MEK1*
MGMT*
P-mTOR (S2448)*
mTOR*
N-Cadherin*
p21**
p27*
p38**
p53*
P-p70S6K (T389)*
p70S6K*
PI3K p85*
P-p90RSK (T359)**
PARP**
P-PDK1 (S241)*
PDK1*
P-PKC alpha (S657)*
PKC alpha*
Progesterone Receptor*
Patched**
PTEN*
Rab25**
P-Rb (S807)*
Rb*
P-S6RP (S235/S236)*
P-S6RP (S240/S244)*
Smad3*
P-Src (Y527)*
Src*
P-STAT3 (Y705)*
Stathmin*
Tau**
TAZ*
TSC2**
VASP**
VEGFR2*
XIAP**
YAP*

-10.6 (-11.0, -10.2)
-1.7 (-1.5, -1.9)
1.4 (1.6, 1.2)
±1.1 (-1.1, 1.1)
-1.2 (-1.2, -1.2)
-1.2 (-1.2, -1.1)
1.3 (1.1, 1.4)
±1.1 (1.2, -1.1)
1.2 (1.2, 1.3)
1.7 (1.8, 1.6)
-1.0 (-1.0, -1.1)
1.1 (1.0, 1.2)
1.1 (1.0, 1.1)
1.0 (1.0, 1.0)
±1.2 (1.2, -1.3)
1.1 (1.2, 1.1)
±1.2 (1.1, -1.2)
±1.2 (-1.3, 1.1)
-2.4 (-2.1, -2.8)
1.2 (1.1, 1.2)
±1.2 (1.1, -1.2)
1.2 (1.1, 1.3)
1.6 (1.4, 1.7)
-1.3 (-1.2, -1.4)
±1.1 (-1.1, 1.1)
±1.3 (-1.5, 1.1)
-1.2 (-1.2, -1.1)
1.2 (1.2, 1.2)
-1.4 (-1.3, -1.5)
1.2 (1.0, 1.3)
1.0 (1.0, 1.0)
1.1 (1.0, 1.2)
±1.1 (1.0, -1.2)
-2.1 (-1.7, -2.6)
-6.1 (-5.2, -7.0)
-1.8 (-1.6, -2.0)
-1.4 (-1.3, -1.6)
±1.2 (1.0, -1.3)
1.1 (1.1, 1.1)
-1.1 (-1.1, -1.1)
1.1 (1.1, 1.0)
1.2 (1.0, 1.4)
1.4 (1.3, 1.5)
±1.3 (1.4, -1.2)
-1.2 (-1.3, -1.1)
1.1 (1.1, 1.0)
±2.3 (-1.8, 2.8)
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Table 3. Changes in expression levels and phosphorylation status in IGF1-treated
MDAMB231 cells in response to GSK3 knockdown. Given fold change values are
averaged from the two independent experiments, and fold change values from each
individual experiment are included in parentheses. “Validated” antibodies, indicated by the
“*” symbol, demonstrate performance for RPPA comparable to an ELISA assay. “Use with
Caution” antibodies, indicated by the “**” symbol, provide high-quality useful information
considered to need confirmation by additional technology.
Antibody
14-3-3 Beta*
14-3-3 Zeta*
P-4EBP1 (S37)*
P-4EBP1 (S65)*
P-4EBP1 (T70)**
4EBP1*
P-ACC (S79)*
AIB-1*
P-Akt (T308)*
P-Akt (S473)*
Akt*
P-AMPK (T172)*
AMPK**
Androgen Receptor*
P-B-catenin (S33/S37/T41)**
B-catenin*
BCL2*
BIM*
P-c-Jun (S73)**
c-Kit*
c-Myc**
Caspase 3**
Caspase 7**
Caveolin-1*
CD31*
Collagen VI*
Cox-2**
c-Raf*
Cyclin B1*
Cyclin D1*
Cyclin E1*
E-cadherin*
P-EGFR (Y992)*
P-ER alpha (S118)*
ETV6**
FAK**
Fibronectin**
FoxO3**
P-FoxO3 (S318)**
GATA3*
P-GSK3 (S21/9)*

Average Fold Change (Exp #1 Fold
Change, Exp #2 Fold Change)
-1.3 (-1.1, -1.4)
1.1 (1.1, 1.2)
±1.5 (-1.7, 1.3)
-1.5 (-1.6, -1.4)
-1.1 (-1.2, -1.1)
1.1 (1.2, 1.1)
2.2 (1.8, 2.6)
1.1 (1.2, 1.0)
-2.2 (-2.7, -1.7)
-6.5 (-11.0, -2.0)
-1.3 (-1.4, -1.2)
1.6 (1.1, 2.0)
1.3 (1.6, 1.1)
-1.4 (-1.4, -1.4)
1.3 (1.4, 1.2)
2.2 (2.4, 2.0)
±1.9 (2.6, -1.3)
1.1 (1.1, 1.2)
1.5 (1.7, 1.4)
-1.1 (-1.1, -1.0)
±1.2 (1.3, -1.1)
±1.1 (-1.1, 1.1)
±1.2 (1.1, -1.2)
-3.2 (-2.8, -3.6)
1.1 (1.0, 1.1)
1.1 (1.0, 1.2)
±1.5 (1.7, -1.3)
1.4 (1.2, 1.6)
1.9 (1.6, 2.2)
±1.2 (-1.2, 1.2)
-1.1 (-1.1, -1.1)
1.2 (1.0, 1.4)
±1.2 (-1.2, 1.2)
1.2 (1.3, 1.1)
-1.4 (-1.7, -1.1)
±1.1 (-1.2, 1.1)
1.3 (1.0, 1.5)
1.1 (1.1, 1.1)
-1.1 (-1.2, -1.1)
1.1 (1.0, 1.2)
-9.0 (-10.3, -7.7)
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GSK3*
P-HER2 (Y1248)*
Hsp27**
IGFBP2*
IGFR1 beta**
IRS1*
JNK2**
P-MAPK (T202)*
P-MEK1/2 (S217)*
MEK1*
MGMT*
P-mTOR (S2448)*
mTOR*
N-Cadherin*
p21**
p27*
p38**
p53*
P-p70S6K (T389)*
p70S6K*
PI3K p85*
P-p90RSK (T359)**
PARP**
P-PDK1 (S241)*
PDK1*
P-PKC alpha (S657)*
PKC alpha*
Progesterone Receptor*
Patched**
PTEN*
Rab25**
P-Rb (S807)*
Rb*
P-S6RP (S235/S236)*
P-S6RP (S240/S244)*
Smad3*
P-Src (Y527)*
Src*
P-STAT3 (Y705)*
Stathmin*
Tau**
TAZ*
TSC2**
VASP**
VEGFR2*
XIAP**
YAP*

-11.6 (-11.2, -12.0)
-1.5 (-1.0, -1.9)
1.4 (1.6, 1.3)
-1.3 (-1.3, -1.2)
-1.4 (-1.2, -1.6)
±1.2 (-1.2, 1.1)
1.2 (1.1, 1.3)
1.2 (1.2, 1.2)
1.4 (1.2, 1.7)
1.6 (1.7, 1.5)
1.1 (1.1, 1.0)
±1.2 (-1.2, 1.3)
±1.1 (-1.1, 1.1)
-1.1 (-1.1, -1.1)
±1.1 (1.2, -1.1)
1.2 (1.3, 1.1)
±1.2 (1.2, -1.1)
±1.4 (-1.3, 1.4)
-1.9 (-2.4, -1.5)
1.2 (1.1, 1.4)
±1.5 (1.1, -1.8)
1.1 (1.0, 1.2)
±1.1 (-1.1, 1.2)
-1.3 (-1.2, -1.4)
-1.1 (-1.3, -1.0)
-1.2 (-1.4, -1.0)
-1.3 (-1.2, -1.4)
1.1 (1.2, 1.0)
-1.4 (-1.4, -1.3)
1.1 (1.1, 1.2)
±1.1 (1.0, -1.2)
1.2 (1.2, 1.3)
1.0 (1.1, 1.0)
-1.9 (-1.6, -2.1)
-4.0 (-4.2, -3.8)
-1.7 (-1.5, -2.0)
-1.4 (-1.2, -1.6)
-1.3 (-1.3, -1.3)
±1.2 (-1.1, -1.3)
-1.1 (-1.2, -1.1)
±1.1 (1.1, -1.1)
1.3 (1.0, 1.6)
1.3 (1.1, 1.6)
±1.2 (1.3, -1.2)
-1.8 (-1.9, -1.8)
-1.1 (-1.0, -1.1)
±2.6 (-1.6, 3.7)
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